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INTRODUCTION 
There is considerable evidence to suggest that dopamine 
(DA), in addition to its role as a precursor of norepine-
phrine (NE) and ephinephrine, has important physiological 
actions in its own right. One physiological action of DA 
seems to be that of a neurotransmitter in the mammalian 
brain (Hornykiewicz, 1966). In addition, there is evidence 
that abnormalities of dopaminergic transmission in the cen-
tral nervous system (CNS) may be of clinical importance. 
For example, dopaminergic over activity in the mesolimbic 
forebrain may be a primary feature in the etiology of 
schizophrenia (Meltzer and Stahl, 1976). 
The drugs used to treat schizophrenia act as DA 
antagonists in the brain (Snyder et al., 1974; Robinson 
et al., 1979). Drugs such as phenothiazines and butyro-
phenones have been shown in clinical studies to be effec-
tive in treating the fundamental symptoms of psychosis 
(Snyder et al., 1974). The results of animal experiments 
indicate that their principal mode of action is blockade 
of DA receptor sites in the CNS (VanRossum, 1966). How-
ever, these neuroleptics are generally nonspecific in 
their effects upon DA neurons and thus, cause major unde-
sireable side effects. 
1 
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If new drugs could be discovered that were more struc-
turally selective for different DA systems, then, perhaps 
these undesireable side effects could be eliminated. In 
order to develop such drugs, a closer look would have to 
be made at different DA systems in an attempt to demonstrate 
DA receptors which are topographically distinct and can 
thus be selectively regulated by both agonistic and antag-
onistic agents. The demonstration of more than one DA 
receptor in mammalian CNS is the subject of the research 
presented in this thesis. 
LITERATURE SURVEY 
I. Dopaminergic Systems in the Central Nervous System 
During the past twenty years there has been an in-
creasing realization of the importance of DA as a neuro-
transmitter in the mammalian brain. As a result, research 
has been focused on demonstrating and mapping out distinc-
tive dopaminergic neuronal tracts in the CNS. DA is not 
present uniformly throughout the brain, but is localized 
in a number of discrete pathways that are still being 
identified and characterized in the brains of laboratory 
animals as well as in postmortem human brains. There is 
good evidence from histofluorescence and biochemical 
studies for at least six distinct DA neuronal tracts: 
1) retinal DA fibers, 2) preoptic anterior hypothalamic 
DA neurons, 3) nigrostriatal DA tract, 4) tubero-infundibular 
DA tract, 5) mesolimbic DA tract, and 6) mesocortical DA 
neurons (Ungerstedt, 197la). A schematic presentation of 
their location and connections is given in Figure 1. 
The largest and by far most thoroughly investigated 
DA tract is the nigrostriatal system (Anden et al., 1964). 
The cell bodies for this tract are located in the pars 
compacta of the substantia nigra, a pigmented nucleus in 
the brainstem'. These cells give rise to a large pathway 
3 
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Figure 1. Major Dopaminergic Pathways (modified from 
Meltzer and Stahl, 1976). 
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that ascends through the lateral hypothalamus, enters the 
crus cerebri in mid-hypothalamus to mix with the myelinated 
bundles of the internal capsule, and then fans out in the 
globus pallidus, finally terminating in the caudate-putamen 
of the neostriatum (Ungerstedt, l97la). The major function 
of the nigrostriatal DA tract is to regulate the neostriatum 
in its control of certain motor movements. Degeneration of 
nigral DA neurons is believed to be the cause of Parkinson's 
disease (Hornykiewicz, 1975). Blockade of DA receptors in 
the neostriatum with neuroleptic drugs is thought to be the 
cause of extrapyramidal syndrome (EPS) (Hornykiewicz, 1975). 
The mesolimbic DA neuronal cell bodies are located 
dorsal to the interpenduncular nucleus in the ventral tegmental 
area and end in terminals just anterior to the caudate 
nucleus in the nucleus accumbens septi, the bed nucleus of 
the stria terminalis, and the deep portion of the olfactory 
tubercle (Ungerstedt, 1971). The mesolimbic DA pathway 
(Anden et al., 1966; Hokfelt et al., 1974) is involved in 
behavioral regulation; according to one popular hypothesis, 
schizophrenia is attributed to overactivity of this particular 
system (Meltzer and Stahl, 1976). 
The presence of cortical DA fibers was first demon-
strated by Thierry et al. (1973). Hokfelt et al. (1974) 
was the first to characterize the histochemical distribution 
of dopaminergic terminals in rat limbic cortex. They des-
cribed terminal plexi in gyrus cingul.i, etorhinal cortex, 
hippocampus, amygdaloid cortex, the most basal layers of 
6 
dorsal frontal cortex, and to a minor extent, the prepyri-
form cortex. It is tempting to assume that the disturbances 
of thinking processes that are an essential feature of many, 
if not all, patients in the schizophrenia spectrum are 
based on dysfunction of these dopaminergic neurons with 
cerebral cortical terminals (Meltzer and Stahl, 1976; Hokfelt 
et al., 1974). 
Cox and Lee (1979) provide evidence for the presence 
of a dopaminergic system within the preoptic anterior 
hypothalamus. It appears that DA receptors present in this 
brain region mediate a fall in core temperature in the rat 
(Cox and Lee, l977b) and in the cat (Quock and Gale, 1974). 
The tubero-infundibular DA tract consists of dopaminergic 
neurons that have their cell bodies in the arcuate nucleus 
of the hypothalamus and have their terminals in the external 
layer of the median eminence. One function of the tubero-
infundibular dopaminergic neurons is to exert a tonic inhibi-
tory effect on the cells of the anterior pituitary which 
synthesize and release prolactin (Hokfelt and Fuxe, 1972). 
In addition, there exists a small number of DA-containing 
neurons in the eye, which seems to send processes to both the 
outer and inner plexiform layers of the retina (Ehringer 
and Falck, 1969). The function of these retinal DA neurons 
has not yet been ascertained. 
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II. Dopaminergic Involvement in the Control of Locomotor 
Activity in Rats 
Previous experiments suggest that DA may play a role 
in the control of locomotor activity in rats. It was re-
ported by Maj et al. (1971) that rats showed an increase 
in locomotor activity following the systemic administra-
tion of L-dopa and a dopa decarboxylase inhibitor. An in-
crease in locomotor activity was also induced by the systemic 
administration of amphetamine (Maj et al., 1972a). In rats 
pretreated with pimozide (DA antagonist) or phenoxybenzamine 
(alpha-adrenergic blocking agent), L-dopa-stimulation and 
that induced by amphetamine was antagonized by pimozide, 
while phenoxybenzamine produced complete or partial inhibi-
tion of hyperactivity induced by L-dopa or amphetamine (Maj 
et al., 1972a). These results show that in the stimulation 
of locomotor activity by these compounds, both central 
catecholamines, DA and NE, play a role. 
Intracerebral injection of DA or drugs interfering with 
DA neurotransmission indicate that locomotion may be related 
to mesolimbic DA neurotransmission. It was found that bi-
lateral injection of DA into the nucleus accumbens of nialamide-
pretreated rats resulted in an enhancement of locomotor activ-
ity (Pijnenburg and VanRossum, 1973). This is in agreement 
with Costal! and Naylor (1975) who reported a dose-dependent 
increase in locomotor activity in rats following the bilateral 
injection of DA into the nucleus accumbens. Only a periodic 
8 
hyperactivity developed after similar injections into the 
tuberculum olfactorium and no change in behavior was ob-
served following injections into the nucleus amygdaloideus 
centralis (Costall and Naylor, 1975). Pijnenburg and Van 
Rossum (1973) reported only a slight to moderate increase 
of locomotor activity following administration of DA into 
the caudate nucleus. 
When NE was administered into the nucleus accumbens of 
rats, an increase in locomotor activity was noted, although 
less intense than after DA (Pijnenburg and VanRossum, 1973). 
Later studies by Pijnenburg et al. (1975) were performed in 
an effort to determine whether the NE-induced increase in 
locomotor activity is a result of an action of NE receptors 
or by stimulation of DA receptors. The authors found that 
the locomotor stimulation induced by administration of 1 
microgram of DA directly into the nucleus accumbens was com-
pletely blocked by haloperidol (HAL). The same dose of HAL 
also completely inhibited the effect of 5 micrograms of NE. 
HAL is considered as a rather specific DA antagonist both 
peripherally and centrally (VanRossum, 1966),with only 
relatively small effects on NE receptors (Anden et al., 1970). 
Since a rather low dose was used, the effect of HAL upon 
the DA and NE-induced locomotor stimulation may be ascribed 
to blockade of DA receptors. Pijnenburg et al. (1975) were 
unable to successfully inhibit the NE-induced hypermotility 
with phentolamine (alpha-adrenergic antagonist) or propranolol 
9 
(beta-adrene~gic antagonist), suggesting that the NE-induced 
stimulation of locomotor activity is indirectly associated 
with DA mechanisms. 
Costall and Naylor (1976) found that systemic adminis-
tration of DA rece,ptor blockers was able to antagonize the 
increase in locomotor activity produced by bilateral applica-
tion of DA to the nucleus accumbens of nialamide-pretreated 
rats. The neuroleptics used in these studies included the 
so-called classical DA repeptor blockers (HAL, fluphenazine, 
pimozide, clothiapine), exhibiting a high degree of EPS, and 
atypical DA receptor blockers (clozapine, sulpiride, thior-
idazine (TRZ)), exhibiting a low incidence of EPS. These 
results further support the involvement of dopaminergic 
mechanisms in the control of locomotor activity. 
There is good evidence to suggest that apomorphine 
(APO) stimulates DA receptors in rat brain (Di Chiara and 
Gessa, 1978; Anden et al., 1967; Iversen, 1975). APO was 
found to produce hypermotility in rats following various 
subcutaneous doses (Buus Lassen, 1974, 1977). It was also 
found that pretreatment of these rats with the neuroleptics 
chlorpromazine (CPZ), TRZ, perphenazine, clozapine, pimozide 
and HAL antagonized the hypermotility. These results are 
in agreement with Ljungberg and Ungerstedt (1978), who found 
that the systemic administration of HAL, TRZ, CPZ, clozapine 
and sulpiride to rats effectively antagonized the locomotor 
activity produced by APO (5.0 mg/kg, s.c.). 
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There is evidence to suggest that the mechanism by which 
APO increases locomotor activity is via the direct stimula-
tion of the DA recepto.r in the nucleus accumbens (Kelly 
et al., 1975; Iversen et al., 1975). Other factors may 
also be involved. The ability of phenoxybenzamine to attenu-
ate APO-induced hypermotility in rats suggests that an in-
direct stimulation of the noradrenergic system plays a role 
in APO-induced hypermotility (Maj et al., 1972b). 
III. Dopaminergic Involvement in Apomorphine-Induced 
Stereotyped Behavior 
Following the administration of APO, a profound change 
in the behavioral pattern of the rat occurs. The charac-
teristic feature of the pattern that emerges is the com-
pulsive repetition of senseless movements. The discon-
tinuous sniffing initially observed in this behavioral 
syndrome is progressively replaced by continuous sniffing, 
exploratory activity and repetitive head and limb movements. 
When the full-blown apomonphine syndrome is reached, the 
rat restricts its locomotor activity to a small area of 
the cage while continuously gnawing, biting and licking. 
This drug-induced syndrome, characterized by compulsive 
behavior o:f a continuous and apparently aimless nature, 
is known as "stereotyped.behavior" (DiChiara and Gessa, 
1978; Randrup and Munkvad, 1974). 
Support for the striatum as the central site of APO 
stereotypy was demonstrated very early (Amsler, 1923). It 
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was found that the ability of APO to produce stereotyped 
behavior was abolished following striatal ablation. In 
support of this view, Ernst and Smelik (1966) showed that 
when administered in microquantities directly into the 
dorsal part of the caudate nucleus or in the globus pallidum, 
APO and dopa could induce stereotyped behavior. When im-
planted in the ventral part of the caudate nucleus, in sub-
thalamic structures or in the substantia nigra, these 
agents were unable to induce stereotypy. 
Since the substantia nigra appears to send fibers to 
the corpus striatum, the finding that this part of the 
mesencephalon contains DA is of great interest. In normal 
rats, DA-storing nerve terminals are found in the neo-
striatum (the caudate nucleus and putamen) (Bertler and 
Rosengren, 1959) and DA-containing nerve cells in the sub-
stantia nigra, mainly in the pars compacta (Kebabian and 
Saavedra, 1976). After electrolytic lesions in the sub-
stantia nigra or the internal capsule, the histochemical 
fluorescence and the DA content of the neostriatum were 
markedly reduced. Removal of the neostriatum produced an 
increased fluorescence of the DA nerve cells of the sub-
stantia nigra. This is strong evidence for the existence 
of nigro-striatal DA neurons, which probably contain most 
or all of the DA present in the neostriatum (Anden et al., 
1964). It has been suggested that the presence of DA in 
this structure is responsible for stereotyped behavior 
12 
and since APO has some structural similarity to DA (Ernst, 
1969) it is able to stimulate DA receptors in the neostriatum 
and evoke stereotypy. 
The mechanism by which APO induces stereotyped behavior 
in rats was demonstrated by Ernst (1967) to be the direct 
stimulation of DA receptors located in the neostriatum. 
Definitive evidence for a direct stimulation by APO of 
striatal DA receptors comes from the study of APO effects 
in rats pretreated intraventricularly with 6-hydroxydopamine 
(6-0HDA) (Schoenfeld and Uretsky, 1972). It was reported 
that the selective destruction of catecholamine-containing 
nerve terminals in the CNS with 6-0HDA caused an increase 
in sensitivity of rats to APO, so that the ED50 for stimu-
lation was halved. These results are in agreement with 
Ungerstedt (1971) who found that in rats whose substantia 
nigra have been bilaterally destroyed with 6-0HDA, a given 
dose of APO produced a compulsive gnawing of greater inten-
sity in the lesioned animals than in the intact ones. These 
results demonstrate that APO acts directly by stimulating 
DA receptors and that denervation induces a supersensitivity 
to its effects. In addition, rats pretreated with central 
DA-antagonists showed no signs of stereotyped behavior fol-
lowing a challenge dose of APO (Niemegeers and Janssen, 
1979). This evidence supports the dopaminergic nature of 
this APO-induced effect. 
Although it is currently accepted that neostriatal 
I 
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dopaminergic systems are important for the development of 
stereotyped behavior patterns, previous studies have shown 
that after electrolytic brain lesioning of the nucleus 
amygdaloideus centralis (a very old nucleus in the archi-
striatum), the more intense aspects of APO stereotypy were 
abolished (Costall and Naylor, 1973a). In addition, there 
is evidence to suggest that the dopaminergic neurons of 
the mesolimbic system may also have a degree of involve-
ment with stereotyped behavior. It was found that APO-
induced stereotyped behavior was reduced when the ascending 
dopaminergic neurons to the mesolimbic system were lesioned. 
Lesioning of both the tuberculum olfactorium and nucleus 
accumbe.ns abolished the sniffing component of APO-induced 
stereotyped behavior while lesion of the stria terminals 
was without effect upon APO stereotypy (Costall and Naylor, 
1973a). 
IV. Dopaminergic Involvement in Neuroleptic-Induced 
Catalepsy 
When neuroleptics are given to animals, catalepsy re-
sults. In this state of sedation, the animals do not move 
spontaneously, and do not respond when they are placed 
in unusual postures or positions, ~ on a tabletop with 
the front limbs elevated using a horizontal bar (Costall 
and Naylor, 1974a). On the other hand, they are not 
hypnotized (as they are with barbiturates, etc.), and their 
muscular power is retained (in contrast to animals sedated 
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with muscle relaxants such as meprobamate, chlordiazepoxide, 
etc.). The cataleptic animals react to painful stimuli and 
right themselves when placed on their backs (Munkvad et al., 
1968). When low doses of the narcotic agonist, morphine, 
are given to animals, catalepsy occurs, providing the observed 
state of immobility is not associated with an increase in 
muscle tone greater than observed during neuroleptic 
catalepsy. However, if increasing the dose of the narcotic 
agonist causes an immobility associated with marked rigidity, 
this state is commonly termed catatonia (Costall and Naylor, 
1974a). 
Practically all neuroleptics produce in man a neuro-
logic syndrome referred to as EPS. The majority of extra-
pyramidal reactions consist of "pseudo parkinsonism" 
(akinesia, muscular rigidity and tremor) and akathisia (a 
syndrome of motor restlessness). In drug-induced parkin-
sonism, the dominating symptom is usually akinesia. The 
akinetic syndrome produced in laboratory animals by neuro-
leptic drugs is. referred to as catalepsy. When testing a 
series of compounds suspected of neuroleptic (extrapyramidal) 
potency, catalepsy is the most common test used for this 
type of evaluation. The clinical activity of the dopaminergic 
antagonists roughly correlates to their ability to induce 
catalepsy in experimental animals (Hornykiewicz, 1975). 
Although this pharmacological screening procedure holds true 
for most typical neuroleptic compounds, a number of atypical 
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neuroleptics (TRZ, clozapine and sulpiride) with antipsychotic 
potency similar to CPZ, were relatively weak inducers of 
catalepsy in rats or devoid of cataleptogenic properties 
altogether (Niemegeers and Janssen, 1979; Biirki et al., 1975). 
There is neuropharmacologic evidence demonstrating that 
dopaminergic antagonists induce catalepsy by acting on the 
corpus striatum. Bilateral electrolytic lesions of the 
corpus striatum were observed to attentuate neuroleptic 
(CPZ)-induced catalepsy (Keffer et al., 1978). This is in 
agreement with Houma and Fukushima (1978) who found that bi-
lateral lesioning of the striatum weakened the catalepsy 
induced by CPZ and TRZ. 
The antiemetic compound, metoclopramide, which has been 
suggested to decrease striatal dopaminergic activity by 
blocking the striatal DA receptors, was found to produce 
a dose-dependent catalepsy in mice (Ahtee and Buncombe, 1974) 
and in rats (Ahtee, 1975). In both of these reports, the 
induction of catalepsy is associated with a five- to six-
fold elevation of striatal homovani1lic acid (HVA), one of 
the main metabolites of DA. This increased striatal HVA 
concentration without any decrease in DA content most prob-
ably indicates that DA formation is increased. APO reduced 
the catalepsy and the increase in striatal HVA concentra-
tion caused by metoclopramide in rats. These findings in 
conjunction with lesion studies previously mentioned sug-
gest that neuroleptics produce catalepsy by blocking DA re-
ceptors in the striatum. 
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The relative importance of the mesolimbic system in 
neuroleptic catalepsy was investigated by placing a lesion 
at the rostral level of the hypothalamus to destroy only 
the ascending pathway to the mesolimbic areas. These 
studies indicate a critical role for the mesolimbic system 
in the mediation of neuroleptic catalepsy since the lesions 
caused a marked reduction of the cataleptic actions of 
spiroperidol, perphenazine, lenperone (LEN), and TRZ. It 
would, therefore, appear that not only extrapyramidal but 
also mesolimbic areas are important for the mediation of 
neuroleptic catalepsy (Cost all and Naylor, 1973b). It was 
further determined that there is a differential involvement 
of mesolimbic areas with the behavioral effects of catalep~y. 
The cataleptic action of HAL and LEN was reduced by lesions 
of the nucleus accumbens and stria terminalis, however, 
ablation of the tuberculum olfactorium did not modify the 
cataleptic action of any agent tested (Costall and Naylor, 
1974b). Even though evidence suggests the involvement of 
mesolimbic areas, Honma and Fukushima (1978) concluded that 
the striatum more than the nucleus accumbens is involved in 
producing catalepsy with neuroleptics, since lesions in the 
nucleus accumbens had fewer effects on catalepsy than did 
those in the striatum. 
It would appear that cholinergic as well as dopaminergic 
mechanisms are important for the control of catalepsy since 
neuroleptic catalepsy can be enhanced or reduced by cholinergic 
or anticholinergic agents respectively (Morpurgo, 1962). 
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Central cholinergic stimulation by arecholine or pilocarpine 
has been found to induce catalepsy. The cataleptic activity 
of these drugs, like that of neuroleptics, was easily 
antagonized by anticholinergic agents, especially scopol-
amine (Zetler, 1971). It is suggested that the interaction 
between the two neurotransmitter systems may take the form 
of a reciprocal balance and that since the striatum is rich 
not only in DA but also in acetylcholine (ACh) then this 
may be a site for the balanced mechanisms (Costall and Naylor, 
l974c). 
The catalepsy and increased concentration of striatal 
HVA induced by neuroleptic drugs can be antagonized by 
anticholinergic drugs (Anden, 1974). There is also other 
evidence that ACh and DA have antagonistic actions in the 
striatum. It has been shown that pilocarpine increases 
the concentration of HVA in the striatum and this increase 
was antagonized by atropine but not by APO (Ahtee and 
Kaariainen, 1974). When rats were pretreated with alpha-
methylparatyrosine (aMT), neuroleptic catalepsy was 
potentiated. It was, therefore, interesting that cholinergic 
catalepsy was also potentiated when catecholamine levels 
were reduced by aMT pretreatment, for this would suggest 
thai a catecholaminergic system normally opposes the 
cholinergic induced effect and, thus, supports the concept 
of a cholinergic-catacholaminergic balance mediating cata-
lepsy (Costall and Naylor, l974c; Ahtee and Kaariainen, 
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1974). Further conceptualization of this ACh-DA balance 
by Gianutsos (1979) is based on a consideration of a re-
ciprocal balance in the striatum between ACh and DA 
where dopaminergic stimulation inhibits cholinergic 
neuronal activity as mentioned previously. Catalepsy may be 
considered as resulting from a net increase in stimulation 
of cholinergic receptors in the striatum. Cholinomimetics 
would then produce catalepsy by directly stimulating these 
receptors while CPZ would produce catalepsy by blocking DA 
receptors and disinhibiting cholinergic neurons leading to 
an increase in the efflux of ACh. 
As to the mechanism of catalepsy, support for this 
ACh-DA balance in the striatum was offered by Honma and 
Fukushima (1978). They showed that bilateral electro-
coagulation of rat striatum decreased neuroleptic-induced 
catalepsy. If electrocoagulation destroyed not only DA 
neurons but also cholinergic neurons, then complete des-
truction of dopaminergic-cholinergic connections would 
cause a reduction in the cataleptogenic activity of HAL. 
On the other hand, it was also shown that microinjection 
of 6-0HDA into the striatum gradually enhanced the 
catalepsy induced by HAL suggesting that removal of the 
inhibitory activity of dopaminergic neurons results in an 
excitation of cholinergic neurons. When Costall and 
Naylor (1973b) destroyed the dopaminergic pathways which 
supply the extrapyramidal brain regions by lesioning the 
lateral hypothalamus, they found that neuroleptic catalepsy 
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was enhanced. If the lesion caused dissruption to the 
dopaminergic component of the postulated dopaminergic-
cholinergic balance operating via the extrapyramidal 
nuclei, cholinergic dominance would result. These studies 
offer support for the involvement of an intrastriatal 
balance between dopaminergic and cholinergic neurons in 
neuroleptic-induced catalepsy. 
V. Dopaminergic Involvement of Apomorphine-Induced 
Hypothermia in Rat 
Since the introduction of specific DA agonists and 
antagonists, evidence has accumulated to suggest that 
stimulation of central DA receptors can bring about thermo-
regulatory changes in several species. In the cat, the 
dose-related fall in body temperature seen after intra-
ventricular injection of DA was blocked by HAL (Kennedy 
and Burks, 1974). In mice, systemically administered APO 
produced a dose-related lowering of body temperature. 
This hypothermic effect is competitively antagonized by 
HAL, pimozide, spiroperiodol, and perphenazine (Fuxe and 
Sjoqvist, 1972; Barnett et al., 1972; Buus Lassen, 1974). 
APO has been consistently reported to cause a decrease 
in the core body temperature of the rat (Kruk, 1972; 
Ary et al., 1977; Cox et al., 1978). These studies also 
show that pimozide or HAL can block the hypothermic action 
of APO. It appears that both DA and APO mediate hypo-
thermic responses through activation of DA receptors. 
The site of action of APO has been demonstrated to 
reside within the preoptic-anterior hypothalamus of the 
rat (Cox and Lee, 1977b, 1979; Cox et al., 1978; Colbec 
20 
and Costentin, 1980). Administration of either DA or APO 
into the preoptic-anterior hypothalamus caused an almost 
immediate rise in tail skin temperature and a concomitant 
fall in core temperature in the rat (Cox et al., 1978). 
Following the systemic injection of pimozide, the dose-
dependent hypothermic response induced by intrahypothalamic 
DA or amphetamine was significantly reduced (Cox and Lee, 
1979). 
It has been reported that tolerance to the hypothermic 
action of APO can occur. Chiel et al. (1974) have shown 
that when rats are tested daily with intraperitoneal in-
jections of APO, the hypothermic response of subsequent 
injections of APO is reduced. It was suggested that a 
decreased sensitivity of the DA receptor was responsible 
for the tolerance to the hypothermic effects of APO. In 
addition, it was found that tolerance to the hypothermic 
effects of APO developed in rats following repeated injec-
tions.of APO in the rostral hypothalamus at the preoptic-
anterior hypothalamic nuclei (Ary et al., 1977). This 
same study showed that although injections of APO in the 
area surrounding the lateral ventricle did induce hypo-
thermia, tolerance to the hypothermic effects of APO was 
not observed. It was therefore proposed that the hypothermic 
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effects of APO are mediated via two different types of DA 
receptors at two different sites: 1) in the rostral hypo-
thalamus where the receptors develop tolerance; and 2) in 
areas surrounding the lateral ventricle, where the receptors 
are resistant to tolerance (Ary.et al., 1977). 
There is considerable evidence to support the concept 
that ACh plays a role in central thermoregulatory mechanisms. 
Iontophoretic injection of ACh into the rostral hypothalamic 
thermoregulatory centers causes a fall in body temperature 
in the rat (Kirkpatrick and Lomax, 1970) and this response 
is abolished by prior systemic injection of atropine in-
dicating a specific effect at cholinergic receptor sites. 
Direct injection of atropine into the rostral hypothalamus 
of the rat produces hyperthermia, presumably due to block-
ade of central cholinergic activity (Kirkpatrick and Lomax, 
1967). 
The interactions between the cholinergic and dopa-
minergic systems in thermoregulation have been studied by 
Glick and Marsanico (1974). In their studies, it was 
found that both APO and pilocarpine induced a dose-dependent 
hypothermia in mice. In addition, when administered to-
gether, the hypothermic effect was greater following a 
combination of the drugs than following either drug alone. 
In the animals treated with APO, either HAL or scopolamine 
were able to antagonize the hypothermic effect, whereas 
only scopolamine antagonized pilocarpine-induced hypo-
thermia. The authors suggest that mechanisms involving 
both dopaminergic and cholinergic neuronal systems con-
tribute to temperature regulation. These data conflict 
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to temperature regulation. These data conflict with Cox 
and Lee (1977a) whose studies showed no evidence to sup-
port the hypothesis that APO-induced hypothermia involves 
a cholinergic link. They found that the anticholinergic 
drugs, scopolamine and atropine were highly effective 
antagonists of oxotremorine-induced hypothermia, but in the 
same doses they were ineffective against the hypothermic 
effect of APO. 
VI. Evidence to Suggest Multiplicity of Dopamine Receptors 
in the Central Nervous System 
Over the last ten years, experience with DA has led 
investigators to consider the DA receptor as something other 
than a single entity. Like other receptor systems, the DA 
receptor has been characterized and subdivided into numerous 
subtypes. In the present review, the contention that 
multiple DA receptor types exist in the CNS will be supported 
by the available evidence. 
In studying the pharmacology of tardive dyskinesias, 
Klawans (1973) found that tardive dyskinesias can occur 
independently of drug-induced parkinsonism and suggested 
that there are two separate populations of DA receptors in 
the striatum which are differentially susceptible to neuro-
leptic blockade. This finding as well as others stimulated 
researchers in psychopharmacology to further examine the 
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the facilitory and inhibitory nature of DA receptor types. 
In 1976, Cools and Van Rossum (1976) hypothesized the 
existence of multiple DA receptor types in mammalian ner-
vous tissue. On the basis of their critical analysis, they 
concluded that there exists two electrophysiologically dis-
tinct types of DA sensitive units, which are each charac-
terized by their own topographical, pharmacological, 
biochemical and ontogenic features. Histochemical experi-
ments on the rat provide evidence that there exists two 
distinct types of DA-terminal structures in the brain. In 
the neostriatum and nucleus accumbens were found structures 
marked by diffuse green DA-fluorescence and structures 
marked by dotted DA-fluorescence respectively. It was 
suggested that these DA-loaded structures within the brain 
contain two populations of DA receptors: excitatory-
mediating DA receptors (DA ), found in the neostriatum 
e 
and inhibitory-mediating DA receptors (DA. ), found in the 
l 
nucleus accumbens. The DA -structures not only appear later e 
in postnatal development than the DAi-structures, but also 
are more sensitive to depletion by aMT and have a higher 
turnover rate (Cools and VanRossum, 1976). It was also 
suggested by Cools and VanRossum (1976) that the DA -e 
receptors are located presynaptically, since both APO and 
HAL are able to interact with the same presynaptic DA 
receptor (Christiansen and Squires, 1974; Costall and Naylor, 
1973c; Seeman, 1974). 
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The general feeling that there may exist more than one 
type of DA receptor has been explored along a number of 
lines. Thus, in gallamine-immobilized cats, the caudate 
nucleus and the nucleus accumbens were perfused by means 
of a push-pull cannula and DA was measured in the perfusate. 
Following probenicid administration, the net effect of sul-
piride, clozapine and TRZ on HVA accumulation was more marked 
in the limbic system than in the striatum whereas HAL 
and CPZ had a similar effect in the two regions (Bartholini, 
1976). Uzan et al. (1978) found similar results in their 
work with mezilamine, a relatively new antipsychotic agent 
related to the atypical neuroleptics. In addition to pro-
ducing a greater accumulation of HVA in the mesolimbic 
area than in the striatum of the rat, mezilamine also 
showed weak cataleptogenic properties. This possibly ac-
counts for the fact that atypical neuroleptics display an 
antipsychotic action and yet cause less EPS than HAL and 
CPZ. 
The accumulation of HVA in rodent brain by neuro-
leptics is thought to be mediated by a neuronal feedback 
mechanism triggered by the blockade of postsynaptic DA 
receptors (Da Prada and Pletscher, 1966; Roos, 1969). If 
this is so, then the DA receptors located in the striatum 
and mesolimbic system should be selectively blocked by the 
classical and atypical neuroleptics, respectively. To test 
this hypothesis, Le Fur et al. (1980) studied the in vivo 
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displacement of the binding of 3H-spiroperidol (a high 
affinity ligand for the DA receptor) by classical and 
atypical neuroleptics. In this study, no correlation 
between regional stimulation of DA turnover and the selec-
tive blockade of DA receptors was found. 
Although Le Fur et al. (1980) were unable to demon-
strate a selective blockade of dopaminergic receptors in the 
striatum by the classical neuroleptics or in the mesolimbic 
system by the atypical neuroleptics, the behavior studies 
of Ljungberg and Ungerstedt (1978) were able to support the 
hypothesis that there exist different DA receptor types in 
the limbic and striatal areas of the brain with differing 
sensitivities to antagonist action. They examined whether 
different types of neuroleptic drugs with different clinical 
profiles may differ in their ability to antagonize two 
different APO-induced behaviors, one characterized by 
compulsive gnawing and another characterized by increased 
locomotion, and whether a difference in their specificity 
would relate to their ability to induce EPS. It was found 
that classical neuroleptic drugs causing high incidence 
of EPS (metoclopramide, HAL, CPZ) predominantly antagonized 
the APO-induced gnawing, while the atypical neuroleptic 
drugs (clozapine, sulpiride, TRZ), showing antipsychotic 
potency together with low incidence of EPS, instead 
antagonized the APO-induced locomotion (Ljungberg and 
Ungerstedt, 1978). 
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Biochemical and electrophysiological studies have pro-
vided evidence for a new dopaminergic receptor whose func-
tion seems to be the regulation of DA influence on postsyn-
aptic cells. The presynaptic neuron itself might contain 
DA autoreceptors because (1) DA and APO can block DA synthesis 
in synaptosomal fractions of rat striatum, and this effect 
is reversed by neuroleptics (Christiansen and Squires, 1974) 
and (2) microiontophoretic application of DA or APO directly 
upon the soma of DA neurons located in zona compacta of 
substantia nigra decreased the firing of these cells, and 
this effect could be blocked by neuroleptic drugs 
(Aghajanian, 1977). These data are consistent with the 
observation that low doses of APO are able to depress loco-
motor function, which is considered to result from a stimu-
lation of presynaptic receptors at doses marginally lower 
than those required to stimulate postsynaptic receptors 
(DiChiara et al., 1976). In addition, binding studies 
indicate that 3H-apomorphine has a prediliction for pre-
synaptic DA receptors (Nagy et al., 1978). The authors 
observed that lesioning with 6-0HDA resulted in a selective 
and extensive retrograde loss of DA neurons in the sub-
stantia nigra, reducing 
3
H-apomorphine binding in this 
structure by 76%. This data provides direct evidence for 
the presence of DA receptors on DA terminals or axons in 
the striatum. 
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Furthermore, from binding studies of H-
neuroleptics and 3H-apomorphine in schizophrenic brains, 




may be measuring preferentially pre- and postsynaptic DA 
receptors, respectively (Lee et al., 1978). This is con-
sistent with the observation that low doses of APO do not 
exacerbate but may alleviate some psychotic symptoms 
(Angristet al., 1975). These data indeed suggest that DA 
neurons themselves contain receptors for DA. 
Although the application of recept0r labelling assays 
has proved useful for many pharmacologists in receptor 
identification and localization, the interpretation of data 
from in vitro binding studies requires great caution. Most 
authors agree that the critical difficulty in labelling of 
receptors with radioactive ligands is that such binding may 
reflect binding to non-specific sites and that sometimes, 
drugs can displace at non-specific binding sites. For this 
reason, perhaps the most important criteria to fulfill in 
order to assess the specificity of binding is drug dis-
placement, necessitating the use of a large number of 
antagonists and agonists belonging to different chemical 
classes (Laduron, 1980). · With regard to the central DA 
receptor, 3H-haloperidol 
pimozide (Baudry et al., 
(Creese et al., 1975), 3H-
l977), 3H-domperidone (Baudry 
t 1 197.9) and 3H-sulp1'r1'de ~ !!!:.__·, , (Theodorou et al., 1979) 
have been used as antagonist ligands, whereas 3H-dopamine 
(Creese et al., 1975), 3H-apomorphine (Seeman et al., 1976) 
and 3H-2-amino-6,7-dihydroxytetrahydronaphthalene (ADTN) 
(Seeman et al., 1979) are the most important agonist ligands. 
It has been suggested that the DA receptor can exist in two 
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interconvertible conformations: the antagonist form and 
agonist form, since DA antagonists and agonists preferentially 
displace the antagonist ligands and agonist ligands respec-
tively (Snyder, 1975). Significance of this agonist-
antagonist receptor state must remain speculative since 
together with the fact that APO has a relatively high affinity 
for the HAL binding sites, a newly available 3H-ligand 
(
3
H-N-propyl-norapomorphine) which can be selectively direc-
ted to either of the two DA receptors has been reported 
(Titeler and Seeman, 1979). 
In addition to the study of the binding of DA agents to 
putative DA receptors, an attempt to increase the knowledge 
about the nature of DA receptors has led investigators to 
study the DA receptor of neural tissue associated with a 
DA-sensitive adenylate cyclase. In the early seventies, 
Greengard's group raised the possibility that the thera-
peutic effects, as well as the extrapyramidal side effects, 
of antipsychotic agents may be attributable, at least in 
part, to their ability to block the activation by DA of 
specific DA-sensitive adenylate cyclases in the human 
brain (Clement-Cormier et al., 1974). Since then, charac-
terization of this enzyme from the caudate nucleus of rat 
brain (Clement-Cormier et al., 1975) as well as geometric 
and stereospecific requirements of antagonists of the DA 
receptor-cyclase compl.ex ( Clement-Cormier et al. , 1979) 




gradient centrifugation procedures, this DA-sensitive 
adenylate cyclase has been regarded as a marker enzyme of 
the postsynaptic membrane (Laduron et al., 1976). 
It is evident that DA receptors can be divided by bio-
chemical or pharmacological criteria. These criteria can 
also be used to separate those DA receptors which are 
linked to the enzyme adenylate cyclase and those which 
are not. The bovine parathyroid provides an example of 
a type of DA receptor which stimulates the enzyme adenylate 
cyclase, whereas the mammatrophs of the anterior pituatary 
contain DA receptors which do not stimulate adenylate cyclase 
(Kebabian and Calne, 1979). It was proposed that the DA 
receptors in these two tissues are examples of two distinct 
categories of receptor designated by Kebabian and Calne 
(1979) as D-1 and D-2 respectively. 
As an example of the location of different DA receptors 
within a tissue, it is of interest to examine the striatum, 
the most extensively studied dopaminergic brain region. 
Destruction of the nigra-striatal neurons with 6-0HDA 
lesions causes no loss of either stria tal (Krueger-, 1976) 
or nigral (Kebabian and Saavedra, 1976) DA-sensitive 
adenyl ate cyclase activity. Conversely, intrastria tal. in-
jection of kainic acid, a rigid glutamic acid analogue, 
destroys neuronal cell bodies in the striatum but spares 
the dopaminergic nerve terminals; this procedure causes 
a substantial loss of striatal DA-sensitive adenylate cyclase 
/ 
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activity but does not diminish the content of DA (Di Chiara 
et al., 1977; Hattori andMcGeer, 1977). In summary, 
neither the autoreceptors of the cell bodies in the nigra 
nor the autoreceptors of the nigro-striatal terminals appear 
to be associated with a DA-sensitive adenylate cyclase. 
Although aDA-sensitive adenylate cyclase has been 
identified in the substantia nigra as well as the striatum 
(Kebabian and Saavedra, 1976), the enzyme occurs on 
cellular elements other than the dopaminergic neurons. 
Recent studies with kainic acid lesions (to remove post-
synaptic DA receptors) and ablations of the cerebral cortex 
provide further evidence to distinguish some of the specific 
binding sites from the DA-sensitive adenylate cyclase in the 
striatum (Schwarcz et al., 1978a). These experiments imply 
that the striatal DA-sensitive adenylate cyclase is located 
predominantly on neurons intrinsic to the caudate; in con-
trast, most of the striatal HAL binding sites are located 
on nerve terminals derived from neurons in the cerebral 
cortex. 
In addition to the D-1 receptors present in the striatal 
region, it has been suggested that the DA receptors in 
guinea pig and carp retinas are all linked to adenylate 
cyclase (Watling et al., 1979). In order to study these 
retinal DA receptors, Watling et al., (1979) utilized 
3
H-domperidone which appears to be a novel ligand (Baudry 
et al., 1979) specific for D-2 receptor binding sites in 
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vitro (Laduron and Leysen, 1979). Since a failure to ob-
serve specific binding of 3H-domperidone to these tissues 
was noted, it implies they contain an apparent homogeneous 
population of D-1 receptors. 
Recent data indicate that both D-1 and D-2 receptors 
exist in the anterior pituitary (Ahnet al., 1979). Thus, 
the adenylate cyclase-linked D-1 anterior pituitary recep-
tor is not associated to prolactin release, but guanosine 
triphosphate (GTP) can modulate DA agonist binding to it 
(Sibley and Creese, 1979). On the other hand, the D-2 
receptor located on the mammatrophs controls prolactin 
release (Caron, 1978), but GTP does not modulate the 
affinity of DA agonists for this site (Sibley and Creese, 
1979). Guanine nucleotides also modulate DA agonist bind-
ing to D-1 receptors on striatal cell bodies (Creese et al., 
1979b). This latter finding is based on the observation 
that destruction of striatal cell bodies with kianic acid 
causes both the loss of DA activated cyclase (Schwarcz 
et al., 1978a) and the loss of the ability of GTP to alter 
DA agonist displacement of 3H-spiroperidol in striatal tis-
sue (Creese et al., 1979a). Thus, GTP can modulate DA 
agonist binding to D-1 receptors in both the striatum 
and the anterior pituitary. 
Considering the. great variety of criteria that are used 
to characterize and subdivide DA receptors into subtypes, 
integrating the available data into one unifying concept 
has become virtually impossible. Although a unified 
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classificati,on of central DA receptors has not yet been 
developed, the available evidence supports the concept of 
multiple DA receptor types in mammalian CNS. 
Statement of the Problem 
Current therapy of schizophrenia involves the use of 
neuroleptic agents which are believed to exert their biolog-
ical activity through the blockade of DA receptors in the 
mesolimbic DA tract. In addition, these drugs block DA 
receptors in the corpus striatum and thus cause side ef-
fects resulting from impaired DA transmission in the extra-
pyramidal system. Neuroleptics also block DA-induced 
inhibition of prolactin release as well as other DA-
regulated nervous functions in the central nervous system. 
The therapeutic problems arising from the non-selectivity 
of currently available drugs towards DA receptors could be 
eliminated, and major advancements into our understanding 
of neurological function and pathophysiology could be made 
if isoreceptors for DA were demonstrated. That such iso-
receptors for DA actually exist may be actual fact; however, 
identification and pharmacological differentiation of these 
DA receptors remains a challenging task. 
The present study was undertaken to further support 
the hypothesis that there might be multiple receptor types 
for DA in mammalian CNS tissue. A series of neuroleptic 
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compounds shall be subjected to a battery of whole animal 
screening procedures in an effort to demonstrate gross 
differences in potency of activity. These pharmacological 
tests shall include antagonism of APO-induced locomotor 
stimulation, stereotyped behavior and thermotropic action 
in rats and the induction of catalepsy by the neuroleptic 
drug. Dose response as well as time-activity relationships 
shall be determined. 
MATERIALS AND METHODS 
Animals 
Adult male rats of the Wistar strain from Simonsen 
Laboratories (Gilroy, California), weighing 150-250g, were 
used in all experiments. On arrival, animals were housed 
in metal cages (50 ~ 35 ~ 20cm) in groups of 15 and exposed 
to a fixed light/dark cycle for a period·of not less than 
one week prior to experimentation (0800-2000:light; 2000-
0SOO:dark). Animals were offered a diet of commercially 
prepared pellets from Ralston Purina Company (St. Louis, 
Missouri) and tap water ad libitum until commencement of 
each experiment, at which time all food and water were 
withdrawn. All experiments were conducted in temperature-
controlled facilities maintained at 23+1°C. 
Drugs 
Apomorphine hydrochloride (APO) obtained from Merck 
and Co. (Rahway, New Jersey) was employed as the dopamine 
(DA) agonist at a standard challenge dose of 2.0 mg/kg. 
Four neuroleptic compounds were also employed in this study. 
From the phenothiazine class, chlorpromazine hydrochloride 
(CPZ) was obtained from Smith Kline & French Laboratories 





DOPAMINE mol wt 153.18 
APOMORPHINE mol wt 267.31 
Figure 2. Structural formulas of Dopamine and the 
dopamine agonist, Apomorphine. 
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LENPERONE mol wt 371.43 
Figure 3., Structural formulas of two butyrophenones, 











mol wt 3 70.56 
Figure 4. Structural formulas of two phenothiazines, 
Chlorpromazine and Thioridazine. 
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(TRZ) from Sandoz Pharmaceuticals (East Hanover, New Jersey). 
From the butyrophenone class, haloperidol lactate (HAL) 
ampules were obtained from McNeil Laboratories (FortWashing-
ton, Pennsylvania) and lenperone hydrochloride (LEN) from 
A. H. Robins Company (Richmond, Virginia). In all experi-
ments, each rat was treated with one of three logarithmically-
spaced doses of either HAL, LEN, CPZ, or TRZ. Double-
distilled water was used as a control. 
All drug solutions were prpeared within 1 hour of 
injection using double-distilled water except for APO, 
which oxidizes in aqueous solution and was thus prepared 
within one minute of injection. The drugs were all admin-
istered intraperitoneally into the lower left quadrant 
of the abdomen using, a 1-ml Tuberculin syringe with a 
5/8-inch, 25-gauge needle. To minimize volume effects, 
all drugs were administered in a constant volume of injec-
tion of 1.0 ml/kg. 
Locomotor Activity 
Locomotor activity was measured in a small soundproofed 
diffusely illuminated room, using a Model "S" Selective 
Activity Meter with printing counter manufactured by Columbus 
Instruments (Columbus, Ohio). Groups of three randomly chosen 
rats were placed in a clear plastic cage with bedding material 
(45 ~ 24 ~ 20cm) and positioned on the activity monitor at 
approximately 1200 hours (Plate 1). At 1530 hours, the 
three rats were pretreated with either a neuroleptic or 
. . . .. <t....: .... 
Plate 1. Experimental setup for measuring Locomotor 
Activity 




double-distilled water. Thirty minutes later, each rat was 
treated with APO at which time monitoring of the group loco-
motor activity commenced. Locomotor activity was measured 
by the monitor every 6 minutes and the total locomotor 
activity score determined for the first 60 minutes follow-
ing APO injection. 
Stereotyped Behavior 
Stereotyped behavior was assessed while the animals 
were individually housed in clear plastic cages (45 ~ 24 
x 20cm) separated by cardboard screens in a diffusely 
illuminated room (Plate 2). Experiments were conducted 
between 1200 and 1600 hours. The experimental animals 
were allowed to acclimate to their environment for at 
least l hour prior to commencement of the experiment. At 
1200 hours, the rats were pretreated in a double-blind 
fashion with one of the four neuropletic drugs or double-
distilled water; 30 minutes later, all animals were chal-
lenged with APO. Thereafter, stereotyped behavior was 
scored at 5-minute intervals for 90 minutes using the 
scoring system summarized in Table I. The individual 
score for each animal over the 90-minute period was the 
sum of. the 18 5-minute readings. 
Catalepsy 
For measurement of catalepsy, the test animals were 
randomly placed in individual clear plastic cages (45 x 24 x 
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Table I. Scoring System for Estimation of the Intensity 
of Stereotyped Behavior . 
Assigned Score Behavior Displayed 
1 Behavior indistinguishable from 
that displayed by untreated 
animals. 
2 Periodic sniffing, and/or 
repetitive head and limb move-
ments. 
3 Continuous sniffing with ex-
ploratory activity, andre-
petitive head and limb movements. 
4 Occasional or periodic gnawing, 
biting, or licking, and explora-
tory activity with continuous 
sniffing. 
5 Persistent and intense gnawing, 
biting, or licking with locomo-
tion restricted to a small area. 
6 Compulsive gnawing, biting, or 
licking at one location. 
Martin and Quock, 1978. 
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20 em) in a diffusely illuminated room. Each cage was 
screened from the others by cardboard screens. Each rat 
was placed in a cage 1 hour prior to drug treatment to 
allow adaptation to the new environment. All observations 
were made between 1200 and 1600 hours. The observation 
table was equipped with a 10-cm high horizontal bar adjacent 
to the cages and blocked from view with carboard screens 
(Plate 3) . Following treatment with one of the four neuro-
leptic drugs or double-distilled water, each animal was 
tested every 15 minutes for catalepsy by placing both front 
limbs over the bar. A cataleptic animal will maintain this 
position for various periods of time dependent upon the 
degree of catalepsy. The moment the animal moved off the 
bar with both front limbs, the reading from the stop watch 
used to measure each animal's duration was then recorded. 
Each animal was placed on the bar two times at each 15-
minute interval within the 90-minute test period to deter-
mine an average duration in seconds . In order to account 
for anima:ls maintaining the imposed position for an 
infinite period of time, a maximum duration of 120 seconds 
was allowed for any observation . The total bar time (in 
seconds) for each animal tested was the sum of six 15-
minute readings, each of which represent the average of two 
test runs . 
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Plate 3. Experimental setup for measuring the degree of . 
Catalepsy 
Plate 4. Experimental setup for measuring Body Temperature 
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Body Temperature 
Core temperature was measured with a Yellow Springs 
Tele-Thermometer (Model 43TA) and thermistor probe in-
serted approximately 4 em. through the rectum while the 
animals were individually housed in metal cages (24 x 
30 x 15cm) (Plate 4). Experiments were conducted between 
1200 and 1600 hours. The experimental animals were allowed 
to acclimate to the testing environment for at least 1 
hour prior to the commencement of the experiment at which 
time baseline body temperatures were measured at 15-minute 
intervals until consistent readings (~ 0.2°C) were obtained. 
The test animals were then pretreated with either a neuro-
leptic drug or double-distilled water 30 minutes prior to 
challenge with either APO or double-distilled water. The 
rectal temperature was then measured every 15 minutes for 
the duration of the expected hypothermia, i.e. 90 minutes. 
Statistics 
The data obtained for the following time activity re-
lationships: 1) the locomotor activity counts for the 60-
minute scoring period; 2) the cumulative stereotyped be-
havior scores for each 15-minute interval; 3) the duration 
of catalepsy for each 15-minute interval; and 4) the change 
in body temperature for each 15-minute interval, were aver-
aged and compared between rats treated with one of three 
logarithmically-spaced doses of either HAL, LEN, CPZ or 
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TRZ and the double-distilled water control using a Friden 
1155 Calculator programed for Dunnett's t-test. 
The molar ED50 of each neuroleptic used in this 
study for each of the pharmacological parameters was deter-
mined with the use of a Hewlett Packard 25C Calculator. 
This calculator was programed for linear regression analysis 
in order to obtain values for y-intercept and slope. In 
order to take into account the molecular weight of each 
neuroleptic used, throughout all calculations, the dose 
of each neuroleptic was expressed as the log mole dose. 
The raw data obtained for each dose of neuroleptic tested 
in all parameters was expressed as a percentage value. In 
the locomotion studies, the locomotor activity count for 
each 60-minute scoring period was expressed as the per-
centage of maximum inhibition of loco.motor activity. In 
the stereotyped behavior studies, the total stereotyped 
behavior score for each animal over a 90-minute period was 
expressed as the percentage of maximum inhibition of stereo-
typed behavior. In the catalepsy studies, the total bar 
time for each animal tested was expressed as the percent-
age of maximum bar time (720 seconds). In the body tempera-
ture studies, the maximum drop in body temperature over the 
90-minute testing period for each animal was expressed as 
the percentage of maximum inhibition of hypothermia. 
Within each parameter tested, the log molar ED50 for 
each neuroleptic was determined by entering each of three 
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log mole doses of a particular neuroleptic into the calcula-
tor as the x-values along with their respective percentage 
figures representing the y-values. By determining the 
equation of the line, the log molar ED
50 
for HAL, LEN, 
CPZ and TRZ within each parameter was calculated by enter-
ing 50 as the y-variable and solving for the x-variable. 




The log molar ED50 of each neuroleptic used in this 
study for each of the pharmacological parameters were 
analyzed quantitatively by means of regression analysis. 
Each parameter was paired with each of the others, making 
a total of 6 pairings. Within each pairing, the log 
molar ED50 for HAL, LEN, CPZ and TRZ of one parameter was 
entered into the Hewlett Packard 25C as the x-values and 
the log molar ED50 for HAL, LEN, CPZ and TRZ for the second 
parameter was entered as the y-values. A correlation co-
efficient was determined for each pairing as well as the line 
of best fit (Table X). This same method of analysis was 
used in determining the correlation coefficient and equa-
tion of the line for each of the 6 pairings of parameters 
with TRZ excluded from the analysis (Table XI). 
RESULTS 
1. Locomotor Activity 
APO 2.0 mg/kg produced a significant increase in 
locomotor activity when injected intraperitoneally into 
rats (Figure 5) compared to a vehicle injection of double-
distilled water. Vehicle-injected rats also showed no 
characteristics of stereotyped behavior whatsoever. Pre-
treatment with three logarithmically spaced doses of HAL, 
LEN, CPZ or TRZ produced a dose-related antagonism of the 
increase in locomotor activity induced by APO 2.0 mgjkg 
with significant antagonism exhibited by HAL at a dose 
of 0.1 mgjkg (Figure 6), LEN at a dose of 0.3 mgjkg 
(Figure 7), CPZ at a dose of 2.0 mg/kg (Figure 8), and 
TRZ at a dose of 8.0 mgjkg (Figure 9). 
2. Stereotyped Behavior 
APO 2.0 mgjkg induced stereotypy when injected intra-
peritoneally into rats. During the 90-minute scoring 
period the rats initially displayed a low intensity of 
stereotyped behavior consisting of periodic to continuous 
sniffing and repetitive head and limb movements. Within 
30 minutes this progressed to a full blown stereotypy con-
sisting of gnawing, biting or licking at one lo-cation which 
frequentlylastedseveral minutes without interruption. 
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Table II. The effect of pretreatment (-30 minutes) with either haloperidol 
lactate, lenperone hydrochloride, chlorpromazine hydrochloride 
or thioridazine hydrochloride on the locomotor activity effects 
of intraperitoneal apomorphine hydrochloride over a 60-minute 
period in male rats. 
Locomotor Activity % of Maximum Inhibition 
Drug Dose N Counts of Locomotor Activity 
Apomorphine 2.0 6 581. 33 + 208. 61 
Haloperidol 0.03 6 418.67 + 132.41 27.98 + 22.78 
0.06 6 237.83 + 58.47 59.09 + 10.06 
0.1 6 63.0 + 15.01 89.16 + 2.58 -
Lenperone 0.03 6 409.50 + 126.33 29.56 + 21.73 
0.1 6 206.33 + 71.96 64.51 + 12.38 
0.3 6 43.17 + 12.45 92.57 + 2.14 
Chlorpromazine 0.5 6 577.50 + 157.71 0.66 + 27.13 
1.0 6 219.0 + 82.58 62.33 + 14.20 
2.0 6 93.0 + 25.55 83.86 + 4.40 -
Thioridazine 2.0 6 521.33 + 146. 33 10.32 + 25.17 
4.0 6 311.0 + 60.95 46.50 + 10.48 
8.0 6 59.33 + 24.20 89.79 + 4.16 
Dose is expressed as mgfkg. Values are reported as the mean + 1.0 SEM. 
N represents the number of groups used. Each group contains 3 rats. 
"" 00 
Figure 5. The mean effects of intraperitoneal apomorphine hydrochloride or 
double-distilled water on the locomotor activity of male rats 
pretreated (-30 minutes) with double-distilled water (vertical 
bars indicate 1.0 SEM). 
Key: H20fH20 =Double-distilled water 1.0 mljkg followed by 
double-distilled water 1.0 mljkg (N=6) 
H20fAPO 2.0 =Double-distilled water 1.0 mlfkg followed 
by apomorphine HCL 2.0 mgj-kg (N=6) 
* = Using Students t-test, the locomotor activity of 
rats treated with APO 2.0 were significantly dif-
ferent from the locomotor activity of rats treated 






















Figure 6. The mean effects of pretreatment (-30 minutes) with haloperidol 
lactate on the locomotor activity effects of intraperitoneal 
apomorphine hydrochloride administered to male rats (vertical 
bars indicate 1.0 SEM). 
Key: H20/APO 2.0 = Double-distilled water 1.0 ml/kg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
HAL 0.03/APO 2.0 =Haloperidol lactate 0.03 mgfkg followed 
by apomorphine HCl 2.0 mg/kg (N=6) 
HAL 0.06/APO 2.0 =Haloperidol lactate 0.06 mgfkg followed 
by apomorphine HCl 2.0 mgfkg (N=6) 
HAL 0.1/APO 2.0 = Haloperidol lactate 0.1 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
* = Significantly different from rats injected with H20/APO 
2.o <R < o.o5) 
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Figure 7o The mean effects of pretreatment (-30 minutes) with lenperone hydro-
chloride on the locomotor activity effects of intraperitoneal apomorphine 
hydrochloride administered to male rats (vertical bars indicate loO SEM)o 
Key: H20/APO 2o0 =Double-distilled water loO mlfkg followed by 
apomorphine HCl 2o0 mgfkg (N=6) 
LEN 0003/APO 2o0 = Lenperone HCl 0003 mgfkg followed by 
apomorphine HCl 2o0 mgjkg (N=6) 
LEN Ool/APO 2o0 = Lenperone HCl Ool mg/kg followed by 
apomorphine HCl 2o0 mgfkg (N=6) 
LEN Oo3/APO 2o0 = Lenperone HCl 0.3 mgfkg followed by 
apomorphine HCl 2o0 mgfkg (N=6) 
* = Significantly different from rats injected with H20fAPO 
2 0 0 (~ < 0 0 05) 
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Figure 8. The mean effects of pretreatment (-30 minutes) with chlorpromazine 
hydrochloride on the locomotor activity effects of intraperitoneal 
apomorphine hydrochloride administered to male rats (vertical bars 
indicate 1.0 SEM). 
Key: H20/APO 2.0 =Double-distilled water 1.0 mlfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
CPZ 0.5/APO 2.0 = Chlorpromazine HCl 0.5 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
CPZ 1.0/APO 2.0 =Chlorpromazine HCl 1.0 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
CPZ 2.0/APO 2.0 = Chlorpromazine HCl 2.0 mgjkg followed by 
apomorphine HCl 2.0 mg/kg (N=6) 
* = Significantly different from rats injected with H20/APO 
2.0 (P < 0.05) 
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Figure 9. The mean effects of pretreatment (-30 minutes) with thioridazine 
hydrochloride on the locomotor activity effects of intraperitoneal 
apomorphine hydrochloride administered to male rats (vertical bars 
indicate 1.0 SEM). 
Key: H20/APO 2.0 = Double-distilled water 1.0 ml/kg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
TRZ 2.0/APO 2.0 =Thioridazine HCl 2.0 mgjkg followed by 
apomorphine HCl 2.0 mg/kg (N=6) 
TRZ 4.0/APO 2.0 = Thioridazine HCl 4.0 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
TRZ 8.0/APO 2.0 = Thioridazine HCl 8.0 mgfkg followed by 
apomorphine HCl 2.0 mg/kg (N=6) 
* = Significantly different from rats injected with H20/APO 
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The behavior displayed then becomes progressively less in-
tense until it becomes undistinguishable from that dis-
played by untreated animals approximately 60 minutes fol-
lowing treatment with apomorphine. 
At all doses tested, HAL, LEN, CPZ and TRZ reduced the 
stereotypy score produced by APO at each time interval over 
the 90-minute testing period and reduced the total stereo-
typy score produced by APO in a dose-related manner (Figures 
10, 11, 12, 13). The lowest dose of TRZ used to block APO-
induced stereotypy was still higher than the highest doses 
of the other neuroleptics tested. 
3. Catalepsy 
The neuroleptic agents, HAL, LEN, CPZ and TRZ were all 
found to induce a dose-dependent cataleptic state when injec-
ted intraperitoneally into the rat. However, a cataleptic 
state was not induced in rats following intraperitoneal 
injection with double-distilled water. Catalepsy was in-
duced in the rat with HAL at doses of 0.3 to 3.0 mgfkg, LEN 
at doses of 0.5 to 2.0 mgfkg, CPZ at doses of 4.0 to 9.0 
mgfkg and TRZ at doses of 10.0 to 40.0 mgfkg. The highest 
dose of each neuroleptic tested induced a cataleptic state 
which was highly significantly different from vehicle-injected 
rats at all time intervals tested (Figures 14, 15, 16, 17). 
A cataleptic state was not induced by TRZ at doses less than 
10 mgfkg. This dose of TRZ was still higher than the highest 
Table III. The effect of pretreatment (-30 minutes) with either haloperidol 
lactate, lenperone hydrochloride, chlorpromazine hydrochloride or 
thioridazine hydrochloride on stereotyped behavior produced by 
intraperitoneal apomorphine hydrochloride over a 90-minute period 
in male rats. 
Drug Dose N 
Apomorphine 2.0 9 
Haloperidol 0.03 6 
0.06 6 
0.1 6 
Lenperone 0.03 6 
0.1 6 
0.3 6 
Chlorpromazine 0.5 7 
1.0 9 
2.0 8 





55.78 + 0.83 
40.0 + l. 59 
31.0 + 2.02 
19.83 + 0.48 
44.83 + l. 54 
29.33 + 2.43 
21.17 + l. 30 
46. 7l + 2. 02 
34.11 + 2. 24 
22.63 + 1.36 
35.11 + 1.65 
26.14 + 0.83 
20.57 + 0.75 
% of Maximum Inhibition 
of Stereotyped Behavior 
28.29 + 2.85 
44.42 + 3.62 
64.44 + 0.86 
16.64 + l. 37 
47.41 + 4.36 
62.05 + 2.33 
16.25 + 3.62 
38.85 + 4.01 
59.44 + 2.44 
37.05 + 2.95 
53.13 + 1.49 
63.12 + 1.35 
Dose is expressed as mgjkg. Values are reported as the mean + 1.0 SEM. 
N represents the number of animals used. 
(J) 
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Figure 10. The mean effects of pretreatment (-30 minutes) with haloperidol 
lactate on stereotyped behavior produced by intraperitoneal 
apomorphine hydrochloride administered to male rats (vertical 
bars indicate 1. 0 SEM). 
Key: H20/APO 2.0 =Double-distilled water 1.0 mlfkg followed by 
apomorphine HCl 2.0 mgfkg (N=9) 
HAL .03/APO 2.0 = Haloperidol lactate 0.03 mgfkg followed 
by apomorphine HCl 2.0 mgfkg (N=6) 
HAL .06/APO 2.0 = Haloperidol lactate 0.06 mgfkg followed 
by apomorphine HCl 2.0 mgfkg (N=6) 
HAL 0.1/APO 2.0 = Haloperidol lactate 0.1 mgfkg followed 
by apomorphine HCl 2.0 mgfkg (N=6) 
* = Significantly different from rats injected with H20/APO 
2.0 CR < o.o5) 
** = Highly significantly different from rats. injected with 
H20fAPO 2.0 (P < 0.01) 
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Figure 11. The mean effects of pretreatment (-30 minutes) with lenperone 
hydrochloride on stereotyped behavior produced by intraperitoneal 
apomorphine hydrochloride administered to male rats (vertical bars 
indicate 1.0 SEM). 
Key: H20/APO 2.0 = Double-distilled water 1.0 mlfkg followed by 
apomorphine HCl 2.0 mgfkg (N=9) 
LEN .03/APO 2.0 = Lenperone HCl 0.03 mg/kg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
LEN .01/APO 2.0 = Lenperone HCl 0.1 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
LEN 0.3/APO 2.0 = Lenperone HCl 0.3 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
* = Significantly different from rats injected with 
H20/APO 2.0 (P < 0.05) 
** = Highly significantly different from rats injected 
with H20fAPO 2.0 (P < 0.01) 
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Figure 12. The mean effects of pretreatment (-30 n1inutes) with chlorpromazine 
hydrochloride on stereotyped behavior produced by intraperitoneal 
apomorphine hydrochloride administered to male rats (vertical bars 
indicate 1.0 SEM). 
Key: H20/APO 2.0 =Double-distilled water 1.0 mljkg followed by 
apomorphine HCl 2.0 mg/kg (N=9) 
CPZ 0.5fAPO 2.0 = Chlorpromazine HCl 0.5 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=7) 
CPZ l.OfAPO 2.0 = Chlorpromazine HCl 1.0 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=9) 
CPZ 2.0/APO 2.0 = Chlorpromazine HCl 2.0 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=8) 
** = Highly significantly different from rats injected with 
H20/APO 2.0 (P < 0.01) 
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Figure 13. The mean effects of pretreatment (-30 minutes) with thioridazine 
hydrochloride on stereotyped behavior produced by intraperitoneal 
apomorphine hydrochloride administered to male rats (vertical bars 
indicate 1.0 SEM). 
Key: H20/APO 2.0 = Double-distilled water 1.0 mljkg followed by 
apomorphine HCl 2.0 mgjkg (N=9) 
TRZ 9/APO 2.0 = Thioridazine HCl 9.0 mgjkg followed by 
apomorphine HCl 2.0 mgjkg (N=9) 
TRZ 12/APO 2.0 = Thioridazine HCl 12.0 mgjkg followed by 
apomorphine HCl 2.0 mgjkg (N=7) 
TRZ 16/APO 2.0 = Thioridazine HCl 16.0 mgjkg followed by 
apomorphine HCl 2.0 mgfkg (N=7) 
* = 
** = 
Significantly different from rats injected with H20/APO 
2 . 0 (_)C < 0 . 05) 
Highly significantly different from rats injected with 
H20/APO 2.0 CR < 0.01) 
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Table IV. The effect of treatment with either haloperidol lactate, lenperone 
hydrochloride, chlorpromazine hydrochloride or thioridazine hydro-
chloride on the ability of male rats to maintain a cataleptic posi-
tion over a 90-minute testing period. 
% of Maximum 
Drug Dose N Total Bar Time Bar Time 
Haloperidol 0.3 7 120.57 + 21.25 16.75 + 2.95 
l.O 7 377.71 + 38.17 52.46 .± 5.30 
3.0 7 654.14 + 15.66 90.85 + 2.18 
Lenperone 0.5 8 91. 38 + 14. 32 12.69 + 1.99 
l.O 9 305.33 + 56.51 42.41 + 7.85 
2.0 8 588.88 + 25.33 81.79 + 3.52 
Chlorpromazine 4.0 8 72.25 + 10.09 10.03 + 1.40 
6.0 6 346.33 + 22.77 48.10 + 3.16 
9.0 6 598.00 + 32.42 83.06 + 4.50 
Thioridazine 10.0 7 69.57 + 8.04 9.66 + 1.12 
20.0 8 314.25 + 21.41 43.64 + 2.97 
40.0 8 541.12+12.28 75.16 + 1.70 
Dose is expressed as mgjkg. Values are reported as the mean + 1.0 SEM. 
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Figure 14. The mean effects of treatment with haloperidol lactate on the 
ability of male rats to maintain a cataleptic position (vertical 
bars indicate 1.0 SEM) 
Key: H20 = Double-distilled water 1.0 mlfkg (N=6) 
HAL 0.3 = Haloperidol lactate 0.3 mg/kg (N=7) 
HAL 1.0 = Haloperidol lactate 1.0 mg/kg (N=7) 
HAL 3.0 = Haloperidol lactate 3.0 mgfkg (N=7) 
* ~ Significantly different from rats injected with 
H20 (P < 0.05) 
** = Highly significantly different from rats injected 
with H20 (P < 0.01) 
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Figure 15. The mean effects of treatment with 1enperone hydrochloride on 
the ability of male rats to maintain a cataleptic position 
(vertical bars indicate 1.0 SEM). 
Key: H20 =Double-distilled water 1.0 mlfkg (N=6) 
LEN 0.5 = Lenperone HCl 0.5 mgfkg (N=8) 
LEN 1.0 = Lenperone HCl 1.0 mgfkg (N=9) 
LEN 2.0 = Lenperone HCl 2.0 mgfkg (N=8) 
* = Significantly different from rats injected with 
H20 (P < 0.05) 
** = Highly significantly different from rats injected with 
H20 (P < 0.01) 
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Figure 16. The mean effects of treatment with chlorpromazine hydrochloride on 
the ability of male rats to maintain a cataleptic position (vertical 
bars indicate 1.0 SEM). 
Key: H20 = Double-distilled water 1.0 ml/kg (N=6) 
CPZ 4.0 = Chlorpromazine HCl 4.0 mgfkg (N=8) 
CPZ 6.0 = Chlorpromazine HCl 6.0 mgfkg (N=6) 
CPZ 9.0 = Chlorpromazine HCl 9.0 mgfkg (N=6) 
* = Significantly different from rats injected with 
H20 <R < 0.05) 
** = Highly significantly different from rats injected 
with H20 (P < 0.01) 
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Figure 17. The mean effects of treatment with thioridazine hydrochloride on 
the ability of male rats to maintain a cataleptic position (vertical 
bars indicate 1.0 SEM). 
Key: H20 = Double-distilled water 1.0 ml/kg (N=6) 
TRZ 10 = Thioridazine HCl 10.0 mgjkg (N=7) 
TRZ 20 = Thioridazine HCl 20.0 mgjkg (N=S) 
TRZ 40 = Thioridazine HCl 40.0 mgjkg (N=S) 
* = Significantly different from rats injected with 
H20 <R < 0.05) 
** = Highly significantly different from rats injected 









doses of the other neuroleptics tested. 
4. Body Temperature 
APO 2.0 mgfkg produced a dose-related hypothermia when 
injected intraperitoneally into rats. The maximum drop in 
body temperature, -1.08° + 0.12°C (mean~ SEM), occurred 
15 minutes following the injection of APO. Pretreatment 
with HAL at 0.1 and 0.3 mgfkg highly significantly antagon-
ized the maximum drop in body temperature induced by APO 
2.0 mgfkg (Figure 19). Pretreatment with HAL 0.03 mg/kg 
potentiated the hypothermic action of APO between 30 and 
90 minutes following the APO injection (Figure 19). When 
tested alone, intraperitoneal HAL 0.3 mg/kg did not sig-
nificantly affect body temperature in the rat (Figure 18). 
Pretreatment with LEN at 0.3 and 1.0 mgfkg highly signifi-
cantly antagonized the maximum drop in body temperature 
induced by APO 2.0 mgfkg (Figure 20). Pretreatment with 
LEN 0.1 mg/kg potentiated the hypothermic action of APO 
between 30 and 90 minutes following the APO injection to a 
degree that was not significant (Figure 20). When tested 
alone, intraperitoneal LEN 1. 0 mgfkg did not significantly 
affect body temperature in the rat (Figure 18). Pretreat-
ment with CPZ at 1.7 and 3.0 mgfkg highly significantly 
antagonized the maximum drop in body temperature induced by 
APO 2.0 mg/kg (Figure 21). Pretreatment with CPZ 1.0 mgfkg 
potentiated the hypothermic action of APO between 30 and 90 
minutes following the APO injection to a significant degree 
~~"" I 
Table V. The effect of pretreatment (-30 minutes) with either haloperidol lactate, 
lenperone hydrochloride, chlorpromazine hydrochloride or thioridazine 
hydrochloride on the rectal temperature effects of intraperitoneal 



































Maximum Drop in 
Body Temperature 
-1.08 + 0.12 
-l. 03 + 0.08 
-0.50 + 0.15 
0 -
-0.97 + 0.15 
-0.30 + 0.11 
0 
-1.14 + 0.09 
-0.73 + 0.13 
-0.39 + 0.09 
-1.12 + 0.13 
-0.72 + 0.09 
-0.30 + 0.10 
% of Maximum Inhibi-

























Dose is expressed as mgfkg. Values are reported as the mean + 1.0 SEM. 




Figure 18. The mean effects of intraperitoneal haloperidol lactate, 
lenperone hydrochloride, chlorpromazine hydrochloride or 
thioridazine hydrochloride on the rectal temperature of 
male rats (vertical bars indicate 1.0 SEM). 
Key: H20 = Double-distilled water 1.0 mlfkg (N=6) 
HAL 0.3 =Haloperidol lactate 0.3 mgfkg (N=6) 
LEN 1.0 = Lenperone HCl 1.0 mgfkg (N=6) 
CPZ 3.0 = Chlorpromazine HCl 3.0 mgfkg (N=6) 
TRZ 3.0 = Thioridazine HCl 3.0 mgfkg (N=6) 
* = Significantly different from rats injected with H20 
(P < 0.05) 
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Figure 19. The mean effects of pretreatment (-30 minutes) with haloperidol 
lactate on the body temperature effects of intraperitoneal apomorphine 
hydrochloride administered to male rats (vertical bars indicate 1.0 
SEM). 
Key: H20/APO 2.0 = Double-distilled water 1.0 mlfkg followed by 
apomorphine HCl 2.0 mgfkg (N=9) 
HAL .03/APO 2.0 =Haloperidol lactate 0.03 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
HAL 0.1/APO 2.0 =Haloperidol lactate 0.1 mgfkg followed 
by apomorphine HCl 2.0 mgfkg (N=6) 
HAL 0.3/APO 2.0 =Haloperidol lactate 0.3 mgfkg followed 
by apomorphine HCl 2.0 mgfkg (N=6) 
* = Significantly different from rats injected with H20/APO 
2. 0 (~ < 0. 05) 
** = Highly significantly different from rats injected with 
H20/APO 2.0 (~ < 0.01) 
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Figure 20. The mean effects of pretreatment (-30 minutes) with lenperone 
hydrochloride on the body temperature effects of intraperitoneal 
apomorphine hydrochloride administered to male rats (vertical 
bars indicate 1.0 SEM). 
Key: H20fAPO 2.0 = Double distilled water 1.0 mlfkg followed by 
apomorphine HCl 2.0 mgfkg (N=9) 
LEN 0.1/APO 2.0 = Lenperone HCl 0,1 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
LEN 0.3/APO 2.0 = Lenperone HCl 0.3 mgjkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
LEN 1.0/APO 2.0 = Lenperone HCl 1.0 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
* = Significantly different from rats injected with 
H20/APO 2.0 CE < 0.05) 
** = Highly significantly different from rats injected with 
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Figure 21. The mean effects of pretreatment (-30 minutes) with chlorpromazine 
hydrochloride on the body temperature effects of int.raperitoneal 
apomorphine hydrochloride administered to male rats (vertical bars 
indicate 1.0 SEM) 
Key: H20/APO 2.0 =Double-distilled water 1.0 mlfkg followed by 
apomorphine HCl 2.0 mgfkg (N=9) 
CPZ 1.0/APO 2.0 = Chlorpromazine HCl 1.0 mgjkg followed by 
apomorphine HCl 2.0 mgfkg (N=8) 
CPZ 1.7/APO 2.0 = Chlorpromazine HCl 1.7 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
CPZ 3.0/APO 2.0 = Chlorpromazine HCl 3.0 mgjkg followed by 
apomorphine HCl 2.0 mgjkg (N=9) 
* = Significantly different from rats injected with H20/APO 
2.0 (~ < 0.05) 
** = Highly significantly different from rats injected with 
H20JAPO 2.0 (~ < 0.01) 
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Figure 22. The mean effects of pretreatment (-30 minutes) with thioridazine 
hydrochloride on the body temperature effects of intraperitoneal 
apomorphine hydrochloride administered to male rats (vertical bars 
indicate 1.0 SEM). 
Key: H20/APO 2.0 = Double-distilled water 1.0 ml/kg followed by 
apomorphine HCl 2.0 mgfkg (N=9} 
TRZ 1.0/APO 2.0 = Thioridazine HCl 1.0 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
TRZ 1.7/APO 2.0 = Thioridazine HCl 1.7 mgfkg followed by 
apomorphine HCl 2.0 mgfkg (N=6) 
TRZ 3.0/APO 2.0 = Thioridazine HCl 3.0 mgfkg followed by 
apomorphine Hcl 2.0 mgfkg (N=6} 
* = Significantly different rats injected with H20/APO 2.0 
(): < 0.05) 
** = Highly significantly different from rats injected with 
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at the 45 and 60-minute time intervals (Figure 21). When 
tested alone, CPZ 3.0 mgfkg significantly lowered the body 
temperature of the rat 30 and 45 minutes following intra-
peritoneal injection (Figure 18). The body temperature 
dropped to a maximum of -0.48 _! 0.18°C (mean_! SEM) at the 
45-minute time interval. The maximum drop in body tempera-
ture induced by APO 2.0 mgfkg was highly significantly 
antagonized when rats were pretreated with TRZ 3.0 mgfkg 
and significantly antagonized with a pretreatment dose of 
1.7 mgfkg (Figure 22). Pretreatment with TRZ 1.0 mgfkg 
potentiated the hypothermic action of APO between 30 and 90 
minutes following the APO injection to a degree that was 
not significant (Figure 21). When tested alone, TRZ 3.0 
mgfkg did not significantly affect body temperature in the 
rat (Figure 17). 
5. Regression Analysis 
The log molar ED50 of HAL, LEN, CPZ, and TRZ of one of 
the four pharmacological parameters measured were .compared 
to each of the other three using regression analysis. In 
this analysis, the correlation coefficients of body tem-
perature compared to stereotyped behavior, locomotor ac-
tivity and catalepsy were 0.92, 0.94 and 0.92, respectively, 
while in the analysis of the other three pairings of 
pharmacological parameters, all had correlation coefficients 
of 0.99 (Table X). In this analysis, only the log molar 
ED
50 
of TRZ on its ability to block APO-induced hypothermia 
compared to the log molar ED 50 of TRZ on its ability to 
block APO-induced stereotyped behavior and locomotor 
activity and its ability to induce catalepsy deviates 
91 
from the regression line when comparing one pharmacological 
parameter to each of the others (Figures 23, 24, 25, 26, 
27, 28). 
In order to further examine this observation, TRZ 
was excluded from the regression analysis and only the log 
molar ED
50 
values of HAL, LEN and CPZ between one pharma-
cological parameter and each of the others were compared. 
The correlation coefficients of body temperature compared 
to stereotyped behavior, locomotor activity and catalepsy 
improved to 0.99, 0.98 and 0.99, respectively, (Table XI). 
The regression lines generated in this analysis further 
demonstrate the deviation of TRZ from the regression line 
when body temperature is compared to each of the other 
pharmacological parameters (Figures 23, 24, 25, 26, 27, 28). 
-~~~~~~~---'~--~~~~~~~~~__:___~. 
Table VI. The ED5o and mole ED5o of haloperidol lactate on its ability to block 
apomorphine hydrochloride-induced effects and to induce catalepsy. 
Parameters ED 50 mole ED50 
Body Temperature 0.09 (0.07-0.11) -7 -7 -7) 1.94 X 10 (1.54 X 10 - 2.45 X 10 
Stereotyped Behavior 0.06 (0.05-0.07) -7 -7 -7 1.40 X 10 (1.26 X 10 - 1.56 X 10 ) 
Locomotor Activity 0.05 (0.04-0.06) -7 -8 -7 1.02 X 10 (8.28 X 10 - 1.25 X 10 ) 
Catalepsy 0.87 (0.57-1.32) -6 -6 -6 1.87 X 10 (1.23 X 10 - 2.83 X 10 ) 
Values for ED50 and mole ED50 are reported as mgfkg (95% C.L.) and molesjkg (95% C.L.), respect1vely. 
<!) 
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Table VII. The ED50 and mole ED50 of lenperone hydrochloride on its ability to 
block apomorphine hydrochloride-induced effects and to induce catalepsy. 
Parameters ED 50 mole ED50 
Body Temperature 0.23 (0.17-0.32) -7 -7 -7 5.74 X 10 (4.20 X 10 - 7.86 X 10 ) 
Stereotyped Behavior 0.14 (0.12-0.17) -7 -7 -7 3.54 X 10 (2.94 X 10 - 4.25 X 10 ) 
Locomotor Activity 0.66 (0.04-0.09) -7 -7 -7 1.52 X 10 (1.02 X 10 - 2.24 X 10 ) 
Catalepsy 1.09 (0.98-1.22) -6 -6 -6 2.68 X 10 (2.40 X 10 - 3.00 X 10 ) 




Table VIII. The EDso and mole ED50 of chlorpromazine hydrochloride on its ability to bloCR apomorphine nydrochloride-induced effects and to induce 
catalepsy. 
Parameters ED 50 mole En50 
Body Temperature 2.37 (2.07-2.70) -6 -6 -6 6.66 X 10 (5.83 X 10 - 7.61 X 10 ) 
Stereotyped Behavior 1.46 (1.43-1.49) -6 -6 -6 4.11 X 10 (4.02 X 10 - 4.20 X 10 ) 
Locomotor Activity 1.02 (0.81-1.28) -6 -6 -6 2.86 X 10 (2.27 X 10 - 3.61 X 10 ) 
Catalepsy 6.20 (5.97-6.44) -5 -5 -5 1.74 X 10 (1.68 X 10 - 1.81 X 10 ) 
Values for ED50 and mole ED50 are reported as mgfkg (95% C.L.) and moles/kg (95% C.L.), respectively. 
<D 
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Table IX. The ED50 and mole ED5o of thioridazine hydrochloride on its ability to 
block apomorphine hydrochloride-induced effects and to induce catalepsy. 
Parameters ED 50 mole ED50 
Body Temperature 2.!7 (1.88-2.50) -6 -6 -6 5.32 X 10 (4.62 X 10 - 6,13 X 10 ) 
Stereotyped Behavior 11.73 (8.80-15.64) -5 -5 -5 2.88 X 10 (2.16 X 10 - 3.84 X 10 ) 
Locomotor Activity 4.08 (3.27-5.09) -5 -6 -5 1.00 X 10 (8,20 X 10 - 1.28 X 10 ) 
Catalepsy 23.28 (22.08-24.53) -5 -5 -5 5.72 X 10 (5.42 X 10 - 6.03 X 10 ) 
Values for ED5o and mole ED50 are reported as mgjkg (95% C.L.) and molesjkg 




Table X. Regression analysis of the logarithm of the molar ED5o of haloperidol 
lactate, lenperone hydrochloride, chlorpromazine hydrochloride and 
thioridazine hydrochloride in a series of four pharmacological parameters; 
body temperature, stereotyped behavior, locomotor activity and catalepsy. 
Analysis of: y-intercept slope r 
------
Body Temperature versus 
Stereotyped behavior l. 74 1.29 0.92 
Body Temperature versus 
Locomotor Activity 1.08 1.22 0.94 
Body Temperature versus 
Catalepsy -0.03 0.86 0.92 
Stereotyped Behavior versus 
Locomotor Activity -0.75 0.92 0.99 
Stereotyped Behavior versus 
Catalepsy -1.21 0.66 0.99 
Locomotor Activity versus 




Table XI. Regression analysis of the logarithm of the molar ED50 of haloperidol 
lactate, lenperone hydrochloride and chlorpromazine hydrochloride (ex-
cluding thioridazine hydrochloride in this analysis) in a series of 
four pharmacological parameters; body termperature, stereotyped be-
havior, locomotor activity and catalepsy. 
Analysis of: y-intercept slope r 
Body Temperature versus 
Stereotyped Behavior -0.41 0.96 0.99 
Body Temperature versus 
Locomotor Activity -0.48 0.99 0.98 
Body Temperature versus 
Catalepsy -1.40 0.65 0.99 
Stereotyped Behavior versus 
Locomotor Activity -0.03 1.03 0.99 
Stereotyped Behavior versus 
Catalepsy -1.10 0.68 0.99 
Locomotor Activity versus 
Catalepsy -1.11 0.66 0.99 
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Figure 23. Regression line of the log molar ED50 of haloperidol lactate, 
lenperone HCl, chlorpromazine HCl and thioridazine HCl in 
stereotyped behavior versus the log molar ED50 of the same 
compounds in body temperature (dashed line). The solid line 
represents the regression line of the log molar ED5o of 
haloperidol lactate, lenperone HCl and chlorpromazine HCl in 
stereotyped behavior versus the log molar ED5o of the same 
compounds in body temperature. (vertical and horizontal bars 
indicate 95% confidence limits; for values, see Tables VI 
through IX; for y-intercept, slope and r values see Tables 
X and XI). 
Key: HAL = Haloperidol lactate 
LEN = Lenperone hydrochloride 
CPZ = Chlorpromazine hydrochloride 
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Figure 24. Regression line of the log molar ED5o of haloperidol lactate, 
lenperone HCl, chlorpromazine HCl and thioridazine HCl in 
locomotor activity versus the log molar ED5o of the same 
compounds in body temperature (dashed line). The solid line 
represents the regression line of the log molar EDso of 
haloperidol lactate, lenperone HCl and chlorpromazine HCl in 
locomotor activity versus the log molar ED5o of the same com-
pounds in body temperature. (vertical and horizontal bars 
indicate 95% confidence limits; for values, see Tables VI 
through IX; for y-intercept, slope and r values, see Tables 
X and XI). 
Key: HAL = Haloperidol lactate 
LEN = Lenperone hydrochloride 
CPZ = Chlorpromazine hydrochloride 
TRZ = Thioridazine hydrochloride 
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Figure 25. Regression line of the log molar ED50 of haloperidol lactate, 
lenperone HCl, chlorpromazine HCl and thioridazine HCl in 
catalepsy versus the log molar. ED5o of the same compounds in 
body temperature (dashed line). The solid line represents the 
regression line of the log molar ED5o of haloperidol lactate, 
lenperone HCl and chlorpromazine HCl in catalepsy versus the 
log molar ED5o of the same compounds in body temperature. 
(vertical and horizontal bars indicate 95% confidence limits; 
for values, see Table VI through IX; for y-intercept, slope 
and r values, see Tables X and XI). 
Key: HAL = Haloperidol lactate 
LEN = Lenperone hydrochloride 
CPZ = Chlorpromizaine hydrochloride 
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Figure 26. Regression line of the log molar ED50 of haloperidol lactate, 
lenperone HCl, chlorpromazine HCl and thioridazine HCl in 
locomotor activity versus the log molar ED50 of the same com-
pounds in stereotyped behavior (dashed line). The solid line 
represents the regression line of the log. molar ED50 of 
haloperidol lactate, lenperone HCl and chlorpromazine HCl in 
locomotor activity versus the log molar ED5o of the same com-
pounds in stereotyped behavior. (vertical and horizontal bars 
indicate 95% confidence limits; for values, see Tables VI 
through IX; for y-intercept, slope and r values, see Tables 
X and XI). 
Key: HAL = Haloperidol lactate 
LEN = Lenperone hydrochloride 
CPZ = Chlorpromazine hydrochloride 
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Figure 27. Regression line of the log molar ED50 of haloperidol lactate, 
lenperone HCl, chlorpromazine HCl and thioridazine HCl in 
catalepsy versus the log molar ED5o of the same compounds in 
stereotyped behavior (dashed line). The solid line represents 
the regression line of the log molar ED50 of haloperidol lactate, 
lenperone HCl and chlorpromazine HCl in catalepsy versus the 
log molar ED5o of the same compounds in stereotyped behavior. 
(vertical and horizontal bars indicate 95% confidence limits; 
for values, see Table VI through IX; for y-intercept, slope 
and r values, see TablesX and XI). 
Key: HAL = Haloperidol lactate 
LEN = Lenperone hydrochlorid 
CPZ = Chlorpromazine hydrochloride 
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Figure 28. Regression line of the log molar ED5o of haloperidol lactate, 
lenperone HCl, chlorpromazine HCl and thioridazine HCl in 
catalepsy versus the log molar ED5o of the same compounds in 
locomotor activity (dashed line). The solid line represents 
the regression line of the log molar ED5 0 of haloperidol 
lactate, lenperone HCl and chlorpromazine HCl in catalepsy 
versus the log molar ED5o of the same compounds in locomotor 
activity. (vertical and horizontal bars indicate 95% con-
fidence limits; for values, see Table VI through IX; for y-
intercept, slope and r values, see Tables X and XI). 
Key: HAL = Haloperidol lactate 
LEN = Lenperone hydrochloride 
CPZ = Chlorpromazine hydrochloride 
















The ultimate objective of this research project was 
to provide further evidence supporting a hypothesis of 
multiple receptor types for DA in mammalian CNS tissue. 
The research in this thesis was to investigate the pos-
sibilities of gross differences in selectivity for DA 
receptors by a series of neuroleptic compounds. In the 
past, few investigators had considered the DA receptor 
as anything other than a single entity, but investigators 
have since turned to determining whether there are DA re-
ceptor subtypes. A stage has now been reached where there 
exist numerous subtypes. However, since these have been 
created from the use of diverse techniques and often times 
from a compilation of data from different laboratories, the 
evidence for the existence of multiple receptor types for 
DA is not always entirely convincing. In this study, all 
the data was gathered and compiled from standardized pro-
cedures in one laboratory and treated by a method of analysis 
similar to that successfully employed by Portoghese (1965) 
in investigating analgesic receptors. 
In this research project, HAL, LEN, CPZ and TRZ were 
subjected to a battery of whole animal screening procedures. 
110 
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These pharmacological tests included antagonism of APO-
induced locomotor activity, stereotyped behavior and 
hypothermia and induction of catalepsy in rats. Systemic 
ED 50 values as well as time-activity relationships were 
determined. 
The present study indicates that the observed effects 
of APO are due to an agonistic effect on dopaminergic 
mechanisms. There is convincing evidence in the litera-
ture correlating the stimulation of central DA receptors 
to rat locomotor activity (Maj et al., 1972b; Buus Lassen, 
1977), stereotyped behavior (Ernst, 1967; Anden et al., 
1967) and hypothermia (Kruk, 1972). There is also evidence 
showing that when DA antagonists are given to rats, catalepsy 
results (Costall and Naylor, 1974a). The ability of the 
DA antagonists HAL, LEN, CPZ and TRZ to abolish the ef-
fects of APO as well as induce a state of catalepsy in the 
present experiments is presumptive evidence that APO and 
the DA antagonists used in this study exert their effects 
via DA receptors. This is in agreement with other findings 
in rats that APO induces locomotor stimulation (Di Chiara 
and Gessa, 1978; Anden et al., 1967; Iversen, 1975), 
stereotypy (Ernst, 1967; Randrup and Munkvad, 1974) and 
hypothermia (Barnett et al., 1972; Cox et al., 1978) and 
that DA antagonists not only block locomotor stimulation, 
stereotypic and hypothermic effects of APO (Buus Lassen, 
1974; 1977; Di Chiara and Gessa, 1978; Fuxe and Sjoqvist, 
1972) but also induce a state of catalepsy in the rat 
(Munkvad et al., 1968). 
112 
The neuroleptics selected for this study include com-
pounds reported to possess similar antipsychotic properties 
with differential incidences of EPS. HAL and CPZ, which 
are used as antipsychotic agents and are known to cause a 
high incidence of EPS (Crane, 1967; Hanlon et al., 1965), 
are referred to as typical neuroleptics. LEN and TRZ, 
which possess antipsychotic properties and non-typical 
neuroleptic properties in animal models (Quock and Louie, 
1977; Ljungberg and Ungerstedt, 1978), give a low degree 
of EPS (Harris, 1975; Carranza and Toro, 1974), and are re-
ferred to as atypical neuroleptics. 
This study shows that the central DA antagonists em-
ployed produce common pharmacological actions. They all 
inhibit APO-induced locomotor activity, stereotyped be-
havior and hypothermia as well as induce catalepsy. There 
are, however, differences in potency. The data obtained 
from this study indicate that in the pharmacological para-
meters measured, HAL is the most potent followed in order 
by LEN, CPZ and TRZ. An exception was observed in the body 
temperature studies where TRZ was slightly more potent than 
CPZ in blocking APO-induced hypothermia. 
TRZ was qualitatively different from HAL, LEN and 
CPZ in that the APO-induced locomotion was blocked at doses 
113 
that did not reduce the APO-induced stereotyped behavior or 
induce catalepsy (Table II, III, IV). The ED50 for TRZ's 
ability to block APO-induced locomotor activity was suf-
ficient to completely block APO-induced hypothermia 
(Table IX). LEN, HAL and CPZ were able to block APO-induced 
locomotor activity at doses that blocked APO-induced stereo-
typed behavior and hypothermia but did not induce catalepsy 
(Table II, III, IV, V). The cataleptogenic ED50 of all four 
DA-antagonists is higher than the anti-apomorphine dose 
(Table VI, VII, VIII, IX). 
The results in the present study on the antagonisms 
of the APO-induced effects agree with previous studies since 
TRZ has been shown not to antagonize APO-induced stereo-
typed behavior or induce catalepsy at doses that blocked 
APO-induced locomotor activity, while HAL and CPZ have been 
shown to antagonize APO-induced locomotor activity and stereo-
typy at equipotent doses (Buus Lassen, 1977; Ljungberg and 
Ungerstedt, 1978; Niemegeers and Janssen, 1979). Although 
pretreatment with LEN was observed to reduce the thermo-
tropic and locomotor actions of APO in rabbits and rats 
while leaving the intensity of APO-induced compulsive 
gnawing unaltered (Quock and Louie, 1977), this study 
clearly shows that LEN antagonized-APO-induced stereotypy 
behavior and hypothermia at doses that block APO-induced 
locomotor activity. This also seems to be inconsistent 
with clinical observations in which LEN was reported to 
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produce a lower-than-expected, based on neuroleptic potency, 
incidence of EPS (Harris, 1975). 
The determination of systemic ED50 values and time-
activity relationships for these neuroleptics in the 
pharmacological parameters previously mentioned will not 
necessarily show selectivity of the agents for DA receptors 
in particular regions of the CNS. However, if the activity 
changes resulting from structurally different neuroleptics 
were compared to one another by means of regression analysis, 
gross differences in selectivity for DA receptors could be 
demonstrated quantitatively. A plot of the log molar ED
50 
of HAL, LEN, CPZ and TRZ in one pharmacological parameter 
versus the log mole ED 50 values of these neuroleptics in a 
second pharmacological parameter should yield a regression 
line with a high correlation coefficient if the compounds 
are binding to receptor sites with identical 3-dimensional 
structure (topography) and chemoselectivity. Conversely, 
if the DA receptors influencing the different pharmacological 
parameters are topographically dissimilar, then the plot of 
the activity in one DA function versus the activity of a 
second DA function would not yield a linear correlation. 
This non-parallel change in activity indicates that the 
drugs being tested are binding to non-identical receptor 
sites (isoreceptors) in causing their various pharmacological 
effects. Assuming that isoreceptors do exist, if the com-
pounds being tested have isoreceptor selectivity then the 
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regression correlation plot showing the activity of a par-
ticular series of compounds in a pharmacological parameter 
governed by a population of DA receptors from one brain 
region may not produce a linear correlation with the 
activity of the same series of compounds in a pharmacol-
ogical parameter gove.rned by a population of DA receptors 
from either the same or another brain region. By the same 
rationale, the extent of activity changes in one pharma-
cological parameter by that same series of compounds would 
be expected to correlate with those compounds' pharma-
cological findings believed to be associated with the same 
population of DA receptors. 
According to this mode of analysis, the activity 
changes reuslting from the different neuroleptics parallel 
each other for the various parameters measured. The plot 
of the pharmacological activity in one DA function versus 
the activity in a second DA function yields a linear cor-
relation in all cases with correlation coefficients ranging 
from 0.92 to 0.99. The parallel changes evident in the 
analysis of each pair of biological functions indicate 
that the compounds are binding to identical receptor 
sites or are not selective among isoreceptors. 
On closer examination of the regression analysis plots, 
only the log molar ED50 of TRZ on its ability to block APO-
induced hypothermia compared to the log molar ED 50 of TRZ 
on its ability to block APO-induced stereotyped behavior and 
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locomotor activity and its ability to induce catalepsy de-
viates from the regression line when comparing the log 
molar ED
50 
of HAL, LEN and CPZ in one pharmacological 
parameter to each of the others (Figure 23, 24, 25, 26, 
27, 28). As it appears that HAL, LEN, CPZ and TRZ exert 
their effects via the DA receptor in the pharmacological 
parameters tested, the peculiarity of TRZ in the regres-
sion analysis plots and its ability to block APO-induced 
hypothermia at doses that do not reduce APO-induced loco-
motor activity or stereotyped behavior or induce a state 
of catalepsy may be due to four different possibilities. 
First, the metabolism of TRZ may result in a more 
active metabolite in the area of the hypothalamic thermo-
regulatory center or a more inactive form in other parts 
of the brain known to contain dopaminergic neuronal 
tracts such as the limbic forebrain or the nigrostriatal 
system. As shown by the studies of Zehnder et al. (1962), 
the metabolism of TRZ is mainly by demethylation of the 
nitrogen atom of the side chain to produce northioridazine. 
The next metabolic, step is oxidation of the two sulphur 
atoms to sulphones and sulphoxides. Northioridazine is 
therapeutically active and the side-chain sulphone deriva-
tive of TRZ is used as a neuroleptic agent (Hopf and Eckert, 
1971). As far as hard knowledge of the metabolic fate of 
neuroleptic drugs is concerned, there is no evidence to 
support a differential metabolism of TRZ or any of the other 
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neuroleptics tested in the brain to account for the results 
obtained with TRZ in this study. 
Second, the apparent selectivity of neuroleptic action 
may result from differential distribution of TRZ in the CNS. 
The distribution pattern for TRZ was determined by Hopf and 
Eckert (1971) in the rat brain using radio-active TRZ. Five 
minutes after i.v. injection, the activity of 14C-thioridazine 
was found to be particularly high in the limbic system where-
as the archicortical hippocampus and the hypothalamus con-
tained little labelled substance. After periods of 1 to 24 
hours the activity was situated mainly in the forebrain, the 
hippocampus, neocortex and thalamus whereas a gradual de-
cline in activity was seen in all other brain regions. Since 
the hypothalamus, which generally has a very permeable 
blood-brain barrier, showed low activity, the effect of the 
barrier cannot be very great. The distribution pattern thus 
cannot be accounted for in simple terms, and is apparently 
determined by a number of different factors. Although the 
pattern of distribution for TRZ reveals a low content in 
the hypothalamus, one cannot rule out the possibility that 
this structure may have a high enough concentration of TRZ 
to evoke a pharmacological response. In order to eliminate 
drug distribution problems, the neuroleptic agents employed 
in this study could be administered in microquantities 
directly into CNS regions where various DA neuronal systems 
are known to be located. This procedure would localize 
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the antagonists in the anatomical regions of the brain where 
DA neuronal functions vary. 
Third, a number of studies have been carried out to 
measure the antimuscarinic potencies of various neuroleptics. 
Binding studies using specific radiolabelled ligands for 
muscarinic receptors indicate that TRZ belongs to the class 
of drugs endowed with potent antimuscarinic properties 
(Miller and Hiley, 1975; Laduron and Ley sen, 1978). 
Similar results were obtained with in vivo studies using 
mydriatic activity in mice and in vitro studies using 
guinea-pig trachea in which TRZ was rated as a potent anti-
muscarinic agent, more so than CPZ or HAL (Pearl et al., 1976) 
There is considerable evidence to support the concept 
that there exists a modulatory relationship between cholinergic 
and dopaminergic neuronal systems in the CNS. The majority 
of the literature concerning the neuroanatomical basis of 
the interaction between these two neurotransmitter systems 
involve the extrapyramidal system (Kelly and Miller, 1975; 
Muller and Seeman, 1974; Morpurgo, 1962). It has been sug-
gested that the antimuscarinic property of TRZ may be re-
sponsible at least in part, for its lack of production of 
EPS when used clinically (Kelly and Miller, 1975). 
In the present study, TRZ's failure to block APO-
induced effects and induce catalepsy at doses which blocked 
APO-induced hypothermia in the rat may be the result of its 
antimuscarinic properties. In addition to TRZ's 
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antidopaminergic property, its antimuscarinic action may 
alleviate the dopaminergic,effects of APO in the hypo-
thalamic thermoregulatory center further enhancing TRZ's 
ability to block APO-induced hypothermia. There is evi-
dence to support the hypothesis that APO-induced hypo-
thermia involves a cholinergic link (Glick and Marsanico, 
1974). It was reported that APO produced dose-dependent 
hypothermic effects in mice which were antagonized by 
scopolamine. However, Cox and Lee (l977a) were unable to 
block APO-induced hypothermia with scopolamine at doses 
l which were highly effective in antagonizing oxytremorine-
-I 
induced hypothermia in rats and mice. Since the exact 
nature of the interaction between the cholinergic and 
dopaminergic systems in thermoregulation is as yet unclear, 
TRZ's antimuscarinic property does not provide the evidence 
to account for the results obtained with TRZ in this study. 
Fourth, there is the possibility of multiple receptors 
for DA in the CNS of the rat. Since TRZ appears to be more 
selective for DA recpetors of the hypothalamic thermo-
regulatory center versus the DA receptors of the corpus 
striatum or the limbic system, the DA receptors governing 
body temperature regulation in the hypothalamus are pre-
sumed to be topographically and chemoselectively dis-
similar to DA receptros in the striatal and limbic systems. 
In recent years, the available data indicates the 
existence of numerous subtypes of DA receptors. The clinical 
--- J 
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observations of Klawans (1973) provided some of the first 
available evidence that supported the existence of two 
types of DA receptors. The concept of a balance between 
the DA exitatory and inhibitory mechanisms was developed 
by Cools and Van Rossum (1976). Their critical review 
developed into a comprehensive account of two distinct DA 
receptor types in striatal and mesolimbic brain areas. 
In behavioral studies classical and atypical neuro-
leptics differentially antagonized APO-induced stereotypy 
and locomotion supporting the hypothesis that there exist 
different DA receptor types in striatal and mesolimbic areas 
of the brain (Ljungberg and Ungerstedt, 1978). Differential 
HVA accumulation in these areas of the brain of rats pre-
treated with classical or atypical neuroleptics further 
support this multiple receptor hypothesis (Bartholini, 1976; 
Uzan et al., 1978). 
Various studies present evidence that the presynaptic 
neuron itself might contain DA autoreceptors (Christiansen 
and Squires, 1974; Aghajanian, 1977) suggesitng pre- and 
postsynaptic DA receptor types. Radiolabelled ligands have 
been used in studies which have employed brain lesion tech-
niques in attempts to locate DA agonist/antagonist binding 
sites presenting further evidence for the existence of pre-
and postsynaptic DA receptors (Nagy et al., 1978; Lee et al., -- -- -- --
1978). 
The study of drug action on the DA-sensitive adenylate 
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cyclase system has provided a criteria for designation of 
multiple categories of DA receptors. The proposed DA 
receptors linked to, or independent of, the DA-sensitive 
adenylate cyclase has been referred to as D-1 and D-2 
respectively (Kebabian and Calne, 1979). Other studies 
with kainic acid lesions and ablations of the cerebral 
cortex have provided further evidence to distinguish at 
least two types of DA receptors in the neostriatum, those 
linked to adenylate cyclase and those independent of the 
enzyme located on axon terminals of corticostriatal fibers 
(Schwarcz et al., l978b). More recent data indicate that 
the bovine anterior pituitary contains two distinct DA 
receptors, one which is not associated with adenylate 
cyclase and which controls prolactin release, the other 
adenylate cyclase linked and regulated by GTP with, as 
of yet, unknown physiological function (Sibley and Creese, 
1979; Caron et al., 1978). 
In view of the present findings, it appears that TRZ 
may be blocking a subclass of DA receptors present in the 
preoptic anterior hypothalamus which are topographically and 
chemoselectively dissimilar to those DA receptors govern-
ing stereotyped behavior, locomotor stimulation and the 
induction of catalepsy in rats. 
To further elucidate this possibility, it would be of 
interest to determine whether or not other atypical neuro-
leptics such as clozapine and sulpiride might share TRZ's 
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differential action upon preoptic anterior hypothalamic DA 
receptors. To determine whether selective antagonism of 
these receptors is a result of actual differences in DA 
receptor types and not simply differential distribution 
within the CNS, central microinjection techniques would be 
used in further studies. 
Expanding the number of pharmacological tests to in-
elude measuring HVA accumulation in the corpus striatum, 
hypothalamus and limbic forebrain following the adminis-
tration of neuroleptic drugs may show differential turnover 
of DA. For example, neuroleptics that produce a selective 
blockade of DA receptor types found predominantly in the 
- 1 
j 
hypothalamus will hence enhance hypothalamic HVA levels 
with little effect elsewhere in the brain. 
The establishment of a DA receptor binding procedure 
would allow for the direct assessment of the extent of 
receptor binding of the neuroleptic agents employed in this 
study in tissues isolated from the striatum, hypothalamus 
and limbic forebrain. The data from these binding studies 
as well as the turnover studies would be subjected to re-
gression analysis along with our pharmacological findings. 
Finally, it would be most useful to expand this study 
to incorporate data from clinical studies using the same 
neuroleptic agents used in the pharmacological, biochemical 
and binding studies. A clinical profile of a neuroleptic 
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with respect to its antipsychotic potency and incidence of 
EPS would indeed make for a more complete study when this 
data is treated along with the other data using regres-
sion analysis. 
CONCLUSIONS 
The present study in male Wistar rats was designed to 
support the hypothesis of multiple receptor types for DA 
in mammalian CNS tissue. Four neuroleptic compounds were 
subjected to a series of whole animal screening procedures 
in an effort to demonstrate gross differences in selec-
tivity for DA receptors. 
The results of the present study indicate that APO-
induced locomotor activity, stereotyped behavior and 
hypothermia are produced in rats through central stimula-
tion of DA receptors. The ability of the neuroleptics 
(HAL, LEN, CPZ and TRZ) to abolish the effects of APO as 
well as induce a state of catalepsy in these experiments 
is evidence that APO and these DA antagonists exert their 
effect via DA receptors. 
This study shows that LEN was able to antagonize APO-
induced stereotyped behavior and hypothermia at doses that 
blocked APO-induced locomotor activity. This finding is 
inconsistent with clinical observations in which LEN was 
reported to produce lower-than-expected EPS (Harris, 1975). 
The results of this study were analyzed by the method 
of regression analysis and revealed parallel activity changes 
124 
125 
from HAL, LEN, CPZ and TRZ for each of the four pharmacolog-
ical parameters measured. Only the log molar ED 50 of TRZ 
on its ability to block APO-induced hypothermia compared 
to the log mole ED
50 
values of TRZ on its ability to block 
APO-induced stereotyped behavior and locomotor activity and 
its ability to induce catalepsy deviates from the regression 
line when comparing the log mole ED50 values of HAL, LEN 
and CPZ in one pharmacological parameter to each of the 
others. 
It may be concluded f:hom this investigation that 
Cl) differential metabolism and/or (ii) differential dis-
tribution of TRZ may be responsible for its differential 
activity at the hypothalamic thermoregulatory center; (iii) 
that TRZ's antimuscarinic action was responsible for en-
hancing its ability to block APO-induced hypothermia; 
and (iv) TRZ may be more selective for a population of 
DA receptors present in the preoptic anterior hypothalamus 
which are topographically dissimilar to DA receptors else-
where in the CNS. 
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